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ABSTRACT
Regulation of DNA replication and repair by diadenosine tetraphosphate
Ryan Cunningham
Thedinucleotide diadenosine 5',5"-P',P*-tetraphosphate (Ap4A)is presentin all animalcells,
typically at levels between 0.05 and 1 uM during normal growth. The level of intracellular
Ap,sA has previously been shown to increase several-fold in response to DNA damage,
although the source and function of this increased Ap4A remains unknown. This project
aimed to investigate the hypothesis that ApsA may promote a mechanismto stall DNA
replication after DNA damage,particularly in response to single strand breaks (SSBs). Using
a sensitive and specific luminometric assay, a 2.1-fold increase in the level of Ap4sA was
detected after treatment of wild-type Chinese Hamster ovary (CHO) cells with the alkylating
agent ethyl methanesulphonate (EMS), which indirectly produces single strand breaks
through base excision repair (BER). A much higher (13-fold) increase was detected when
cells were treated with EMS in combination with cytosine arabinoside (araC), which causes
an accumulation of DNA strand breaks by inhibiting the re-synthesis stage of BER.
Strikingly, an increase of up to 16-fold in the basal level of ApsA was detected in cells
deficient in XRCC1, a scaffold protein which plays a pivotal role in both the SSB repair and
BERprocesses. XRCC1 formsa tight complex with DNAligase IIa (Lig3«a) and targets it to
DNASSBs.Lig3a has previously been found to synthesise Ap4A in vitro and this reactionis
specifically inhibited by the presence of DNA. Thelevelofintracellular Ap4yA wasalso found
to be increased here by using the ligase inhibitor L67 that specifically prevents Lig3a binding
to DNA.Takentogether, these data suggest that Lig3a may be responsible for DNA damage-
related Ap4A synthesis in vivo where it cannot bind its normal DNA substrate. This may be
the case in the early stages of SSB repair since Lig3a would be blocked from binding SSBs
by the transient binding of poly(ADP ribose) polymerase 1 (PARP-1). Interestingly, a more
detailed analysis of cell extracts by HPLC found that a substantial proportion of the Ap4A
accumulating in cells following DNA damage did not co-elute with an Ap4A standard,
suggesting it was modified in some way. This material was found to co-elute with a sample
of ADP-ribosylated Ap4A synthesised in vitro and wasalso sensitive to poly(ADP ribose)
glycohydrolase (PARG) which removes ADP-ribose. Although it has already been reported
to occur in vitro, the observations madehere provide the first evidence that ADP-ribosylated
Ap4A also occurs in vivo and is synthesised in response to DNA damage. This is particularly
interesting since ADP-ribosylated Ap4A synthesised by PARP-1 has previously been shown
to inhibit SV40 DNAreplication in vitro, suggesting it may also carry out this function in
vivo. Also within this project an Ap4A-deficient cell line was engineered by transfection of
wild-type CHO cells with a construct allowing inducible over-expression of NUDT2 Ap4sA
hydrolase. Detailed characterisation of this cell line revealed that this caused a reduction in
the normal endogenous level of ApsA and prevented the usual increase in Ap4yA from
occurring after treatment of the cells with EMS. Furthermore, it was found that this lack of
Ap,Aresulted in an increased sensitivity of cells to EMS providing a strong suggestion of a
functional involvement for ApsA in surviving DNA damage. Taken together, the
observations made in this study suggest that Ap4A is synthesised by Lig3a in response to
DNAdamageand is subsequently ADP-ribosylated by PARP-1. This ADP-ribosylated Ap4sA
may havea role in stalling DNA replication in response to DNA damage and appears to be
important for cell survival following such damage. In summary, this study has made
significant progress in determining the function of Ap4A in animalcell signalling and has
provided newinsights into its proposed role in the DNA damage response.
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CHAPTER1
Introduction
1.1. Introduction to DNA repair
It is essential for every organism to maintain the integrity of its genome so that genetic
material is transferred accurately to successive generations. DNAis constantly subject to a
wide variety of damaging modifications including hydrolysis, oxidation, alkylation, bulky
adduct formation and base mismatches, all of which can be induced by various substances
producednaturally during cellular metabolism. In addition, DNA damagecanalso be induced
by exogenous sources including physical agents such as ionising radiation and ultraviolet
(U.V.) light, as well as chemical agents such as alkylating agents, DNA crosslinking agents
and radiomimetic agents. Eukaryotic cells have evolved a number of mechanisms of DNA
repair, which act on specific types of DNA damage. These DNA repair mechanisms include
single strand break repair (SSBR), base excision repair (BER), nucleotide excision repair
(NER), mismatch repair (MMR), homologous recombination repair (HRR) and non-
homologous end-joining (NHEJ), as well as damage reversal by certain proteins such as
alkyltransferases.
1.2. DNA repair mechanisms
1.2.1. DNAsingle strand break repair (SSBR)and base excision repair (BER)
1.2.1.1 Causes andstructure of DNAsingle strand breaks (SSBs)
A DNAsingle strand break (SSB) is a break in the sugar-phosphate backboneofone strand in
a DNA double helix. If left unrepaired, SSBs can pose seriousthreat to genetic stability and
cell survival by blocking transcription or inducing DNAreplication fork collapse leading to
potentially lethal double strand breaks (DSBs) (Kuzminov, 2001). SSBs are typically
accompanied bythe loss of a single nucleotide at the damage site and the presence of DNA
termini lacking the conventional 5’ phosphate and 3' hydroxyl groups that are necessary for
DNA polymerase and DNA ligase enzymesto carry out repair. These unconventional DNA
ends require various forms of processing before gap-filling and ligation can take place. An
overview of the SSBRprocessis presented in Fig. 1.1 (pg. 18).
It is estimated that several thousand SSBsoccurin each humancell per day, predominantly as
a result of attack by reactive oxygen species (ROS) such as hydrogen peroxide (H203),
hydroxyl radicals (OH’) and superoxide radicals (O2°) which are produced endogenously as a
by-product from oxidative metabolism and are highly reactive due to their unpaired electrons.
These molecules can either directly attack sugar residues, leading to their disintegration and
the formation of a SSB, or can attack DNAbases causing oxidative damage whichindirectly
leads to SSBs by base excision repair (BER) (Lindahl, 1993). Indirect SSBs induced by BER
can also be caused by exogenous agents which cause base damage, such as the DNA
alkylating agents N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), methyl
methanesulphonate (MMS) and ethyl methanesulphonate (EMS). In addition, ionising
radiation (IR) can cause SSBs, either directly through the ionisation of sugar residues or
indirectly by base damage and subsequent BER.A further source of SSBsis the single strand
nicking of DNA by topoisomerase I (Topl), which normally functions to relax DNA
supercoiling prior to DNA replication. Following nicking, a transient Topl1/DNA cleavage
complex is formed and under normalconditions, Top] immediately re-ligates the break after
the DNA hasrelaxed. However, under certain conditions, the ligation activity of Top1 can be
uncoupled from its nicking activity resulting in a SSB with a Top] linked 3’ terminus. The
anti-cancer drug camptothecin acts by binding to the transient Topl1/DNA complex and
stabilisingit, producing this type of break (Hsiangef al., 1985).
1.2.1.2 Poly(ADP-ribose) polymerase 1 (PARP-1) and SSB recognition
SSBsoccurring directly from the disintegration of sugar residues are primarily detected by
poly(ADP-ribose) polymerase 1 (PARP-1). PARP-1 is a 113 kDa enzyme whosecatalytic
activity is directly stimulated by DNA SSBs. The N-terminal region of the protein contains a
DNAbinding domain which acts as a molecular ‘nick sensor’ and allows specific binding of
the protein to DNAin regions containing SSBs (Kameshita ef al., 1984). Introduction of a
SSB in a DNAduplex inducesstrong flexibility in the region, which results in a characteristic
V-shape of the DNA molecule. Very rapidly (<15 seconds) after the break occurs, PARP-1
specifically recognises and binds tothis structure, protecting approximately 7 nucleotides on
each side of the nick from degradation (Ménissier-de Murcia ef al., 1989). The DNA binding
domain of PARP-1 contains two zinc ions, each forming part of a zine finger motif, a
characteristic DNA binding domain found in numerous eukaryotic proteins (Mazen efal.,
1989). These zinc ions are essential for DNA binding function and are chelated by certain
critical cysteine residues (C21/C56 for finger 1 and C125/C162 for finger 2) that are well
conserved between species (de Murciaet al., 1994). The second zinc finger motif appears to
play the most importantrole in the binding of PARP-1 to regions of DNA containing single
stranded breaks (Gradwohlef al., 1990).
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The C-terminal region of the molecule contains both a NAD” binding domain (Kameshitaet
al., 1984) and a catalytic domain whichis responsible for the synthesis of poly(ADP-ribose)
(Simoninef al., 1990). These activities are carried out at low levels by unbound PARP-1, but
are increased 500-fold by activation of the enzyme through binding to a DNA SSB (de
Murcia ef al., 1994). NAD‘is used as a substrate by the enzymein a reaction which produces
both nicotinamide and ADP-ribose, the latter of which is polymerised onto an acceptor
protein, most commonly PARP-1 itself (reviewed in Lindahl ef al., 1995). This ADP-
ribosylation imparts a strong negative charge on the protein, drastically altering its properties
and causing its dissociation from DNAdueto electrostatic repulsion. In the case of PARP-1,
this dissociation may facilitate access to the damaged region of DNA by various repair
enzymes (Caldecott ef al., 1996). The degradation of poly(ADP-ribose) is carried out by
poly(ADP-ribose) glycohydrolase (PARG), which is also required for efficient SSBR
suggesting that poly(ADP-ribosylation) is a tightly controlled element of the repair process
(Davidovie ef al., 2001).
1.2.1.3 X-ray cross complementing protein 1 (XRCC1)
Following binding of PARP-1 to a DNA SSB,the DNArepair protein XRCC1 (x-ray cross
complementing protein 1) is recruited from throughout the nucleus to the region of damage.
This recruitment is mediated by PARP-1, which directly interacts with XRCC1, and is
dependent both on binding of PARP-1 to the DNA and the subsequent auto-poly(ADP-
ribosylation) of PARP-1 (Okanoef al., 2003).
XRCC1 is a 70 kDascaffold protein that plays a critical role in both the SSBR and BER
pathways through direct interactions with a number of important repair proteins. Cells
deficient in XRCC1 are defective in re-joining SSBs and have an increased sensitivity to
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agents that induce the types of DNA damagerepaired by SSBR/BER. XRCC1 contains an N-
terminal domain (NTD) and two BRCT (breast cancer suppressor protein C-terminal)
domains which mediate multiple interactions with various enzymes involvedin all stages of
the SSBR and BERprocesses (Caldecott, 2003). The BRCT1 domainis responsible for the
interaction of XRCC1 with activated PARP-1 and its accumulation at SSBs as discussed
above (Masson et al., 1998; Dantzer et al., 2000). This domain is also involved in the
interaction of XRCC1 with AP endonuclease I (APE1), which hasa role in its recruitment to
strand breaks created indirectly during BER (Vidal et al., 2001). The NTD of XRCC1 binds
to DNA polymerase-B (pol-B), which carries out small gap-filling in both SSBR and BER
(Wilson, 1998) as well as some DNA end-processing activity (Sobol ef al., 2000).
Interestingly, it has recently been shown that the NTD of XRCC1 can exist in either a
reduced or oxidised form with the latter having a muchgreater affinity for pol-B (Cuneo &
London, 2010). The DNA end processing enzymes polynucleotide kinase (PNK) and
aprataxin (APTX) associate with a casein kinase 2 (CK2)-phosphorylated linker region of
XRCC1 located between the two BRCT domains. These interactions are mediated by the
forkhead associated (FHA) domains of PNK/APTX, which specifically target CK2-
phosphorylated peptides (Whitehouseef al., 2001; Luo ef al., 2004). In the case of PNK,this
binding stimulates both the 5’ kinase and 3' phosphatase activities of the enzymein repairing
unconventional DNA ends. A third protein, aprataxin and polynucleotide kinase-like factor
(APLF), also associates with this region, again by means of a FHA domain, and may have a
role in poly(ADP-ribose) signalling during SSBR (Iles ef a/., 2007; Rulten er al., 2008).
Finally, the C-terminal BRCT2 domain of XRCC1 mediates the formation of a tight complex
with DNAligase IIIa (Lig3a), the DNA ligase enzyme primarily responsible for re-sealing
SSBsfollowing SSBR and BER (Caldecott et al., 1994). Most cellular Lig3a is constitutively
bound to XRCC1 andthis interaction appears to be important for maintaining its stability in
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vivo, with the level of Lig3a being reduced by up to 5-fold in XRCC1-deficient cells due to
Lig3a degradation by the proteasome (Caldecott et al., 1995; Moore et al., 2000). XRCC1
also appears to be important in targeting Lig3a to its sites of activity (Cappelli et al., 1997).
1.2.1.4 Base excision repair (BER)
As mentioned above, SSBs can be induced directly by hydrolysis of the sugar-phosphate
backbone of DNA, but mayalso be producedindirectly as part of base excision repair (BER).
BERis the primary cellular mechanism for the repair of various types of DNA base damage
(reviewed in Zharkov, 2008). The initial damage recognition is mediated by one of a number
of DNA glycosylase enzymes, each of which is specific to either a certain type of base
modification or in some cases, a number of related types. DNA glycosylases function to
hydrolyse the N-glycosidic bond between the DNAbaseand the sugar, which causes removal
of the base leaving behind an apurinic or apyrimidinic site (AP site). AP sites themselves are
highly cytotoxic and mutagenic and, if left unrepaired, may re-arrange to generate SSBs. In
addition to action by DNA glycosylases, endogenous molecules such as water and reactive
oxygen species, produced as by-products of oxidative metabolism, may also spontaneously
attack the N-glycosidic bondto directly produce an AP site. AP endonuclease 1 (APE1) is the
major AP endonuclease in mammalian cells and functions to cleave the sugar-phosphate
backbone of DNA to the immediate 5’ side of AP sites (Mol ef al., 2000). Through this
endonuclease activity, APE] is the predominant source of indirect SSBs arising through
BER.The BERprocessandits relationship to SSBR is summarised in Fig. 1.1 (pg. 18).
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1.2.1.5 DNA polymerase B (pol-f) and gap-filling in SSBR and BER
The incised abasic site produced by APE1 allowsthe recruitment of DNA polymerase-f (pol-
B), a small, single-subunit DNA polymerase that primarily functions to fill in gaps during
BER and SSBR (Caldecott ef a/., 1996). Pol-B has a high affinity for the incised abasic sites
produced by APE1 and efficiently binds to the substrate DNA following dissociation of
APE1 (Parsons ef al., 2005). The 8 kDa N-terminal domain of pol-f has 5'-deoxyribose
phosphate (dRP) lyase activity and catalyses the removal of the dRP from the SSB that was
created by APE1. The 31 kDa C-terminal domain contains the DNA polymerase active site
and is responsible for gap-filling. DNA binding of pol-B causes recruitment of the
XRCC1/Lig3a complex to the site by increasing the affinity of this complex for the incised
abasic site (Parsonsef al., 2005).
1.2.1.6 DNA endprocessing in SSBR and BER
DNA SSBs are typically characterised by the presence of DNA termini lacking the
conventional 5' phosphate and 3’ hydroxyl groups that are necessary for DNA polymerase
and DNA ligase enzymes to carry out repair. These unconventional DNA ends require
various forms of processing before gap-filling and ligation can take place. Althoughthedirect
SSBs caused by ROS and IR do commonly have conventional phosphate groupsat the 5'
termini, the 3' termini are normally ‘damaged’ by the presence of either phosphate or
phosphoglycolate groups (Ward, 1998). The former is a major substrate for PNK
(Whitehouse ef a/., 2001), while the latter is primarily removed by APE1 (Winters et al.,
1992; Winters et al., 1994). In contrast, where the break is created indirectly by APE]
incision, the 5’ termini normally possess a deoxyribose phosphate (dRP) group, which is
removed by the dRP lyase activity of pol-B (Sobol ef a/., 2000). It is worth noting thatif this
dRP residue becomesoxidised thenit is no longer a substrate for pol-B and as a result, BER
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then normally proceeds by the long patch pathway (discussed on pg. 16). Where BERis
initiated by bifunctional DNA glycosylase enzymes whichalso possess AP lyaseactivity, the
3' end of the SSB produced can possess either a phosphate group (removed by PNK)or an
a,fh unsaturated aldehyde group (removed by APE1), depending on the mechanism of AP
lyase action (Chen et al., 1991; Izumi et al., 2000; Wiederhold ef al., 2004). Finally, TOP1
linked termini are processed by tyrosyl-DNA phosphodiesterase 1 (TDP1) which removes the
covalently linked peptide to allow subsequent repair (Pouliot et al., 1999).
1.2.1.7 Aprataxin (APTX)andits role in DNA endprocessing
Aprataxin (APTX) wasoriginally identified as a protein defective in the neurodegenerative
disorder ataxia with oculomotor apraxia type 1 (AOA1) (Date ef al., 2001; Moreira ef al.,
2001). It is encoded by the APTYX gene andexists in either a short 19 kDa formor a long 39
kDa form. The N-terminal region of the protein contains a phosphoprotein-binding FHA
domain while the C-terminal contains a zinc finger DNA binding domain (Guevenef ai.,
2004). APTX plays an important role in DNA SSBRand cells deficient in APTX have been
shownto have an increased sensitivity to agents that specifically induce DNA SSBs(Luo et
al., 2004; Mosesso ef al., 2005). The FHA domain of APTX directly interacts with the C-
terminal region of XRCC1, as well as the double strand break (DSB) repair protein XRCC4.
Specific phosphorylation of XRCC1 by CK2 is required for APTX binding. It appears that
APTX forms part of a SSB repair complex including both XRCC1 and Lig3a (Luo ef al.,
2004).
A specific function of APTX appears to be the removal of DNA adenylates that arise from
the abortive ligation of unconventional SSBs that have been modified by oxidative damage.
APTXis the only protein knownto be capable of repairing this type of lesion, and does so by
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catalysing the removal of AMP from the 5' terminus of the break site, which then allows the
strand to act as a substrate for DNAligases to repair the break (Ahel e¢ al., 2006; Rass ef al.,
2007). The C-terminal zinc finger domain is required for efficient binding to DNA-adenylate
complexes and disruption of this motif reduces the DNA-adenylate hydrolase activity. The
catalytic activity of APTX is mediated by a central histidine triad (HIT) domain, a
characteristic motif for a superfamily of proteins with nucleotide hydrolase and transferase
activity (Brenner, 2002).
1.2.1.8 Long patch BER (LP-BER)
Under certain conditions where the 5’ terminus of a strand break cannot be processed, an
alternative BER pathway termed long patch BER (LP-BER) is used which results in the
excision of more than one nucleotide (Frosina et al., 1996; Klungland & Lindahl, 1997). This
involves the continuation of DNA polymerase gap-filling by progressive displacementof the
strand containing the damaged 5' residue. This mechanism is dependent on a complex which
comprises both proliferating cell nuclear antigen (PCNA), a sliding clamp protein which
primarily functions during DNAreplication, and the clamploaderreplication factor C (RFC).
Pol-f itself can carry out strand displacement synthesis when stimulated by PARP-1 and flap
endonuclease-1 (FEN-1) or alternatively, a polymerase switch can occur with DNA
polymerase 8 (pol-8) and/or DNA polymerase ¢ (pol-e) continuing strand synthesis (Prasad et
al., 2000). The flap structure formed is nicked by FEN-1 and the displaced section of DNA
containing the damaged terminusis then excised. Unlike short-patch BER, the XRCC1/Lig3a
complex does not carry out ligation; instead this function is completed by Ligl, which
directly interacts with PCNA (Levin ef al., 1997). PCNAalso directly interacts with XRCC1
(Fan et al., 2004; Uchiyamaet al., 2008) and this may be responsible for the recruitment of
the RFC-PCNA complex to sites of LP-BER (Hashiguchief al., 2007).
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1.2.1.9 Ligation of DNA breaks in SSBR and BER
DNA ligases function to link together DNA strands by catalysing the formation of a
phosphodiester bond to seal the gap. Mammalian DNA ligase enzymes are encodedby three
separate genes, LIG/, LIG3 and LIG4 (reviewed by Tomkinsonef al., 2006). The L/G/ gene
encodes DNAligase I (Lig), which is the primary ligase involved in DNAreplication.It
directly interacts with PCNA and functions to ligate Okazaki fragments during discontinuous
lagging strand synthesis, as well as having an additional role in LP-BER. L/G4 encodes DNA
ligase IV (Lig4), which forms a constitutive complex with XRCC4that is essential for Lig4
stability in vivo. Its primary function is to ligate DNA DSBs during non-homologous end-
joining (NHEJ). The third gene, LJG3 encodes three isoforms of DNA ligase III (Lig3). The
main form, Lig3a forms a tight complex with XRCC1 and functions to ligate DNA strand
breaks following SSBR and BER.The second isoform Lig3B is similar to Lig3a, apart from
the fact that it lacks the C-terminal region required for XRCC1 interaction. It is expressed
only in the testis and is presumedto havea role in genetic recombination during meiosis. The
final isoform, mtLig3, is exclusively involved in maintaining the integrity of the
mitochondrial genome.
The primary role of Lig3a appears to be in the repair of damage-induced DNAbreaks. An N-
terminal zinc finger domain has been identified which shares homology with the two zinc
finger domains present in PARP-1 that are responsible for detection and binding to DNA
SSBs (Wei ef al., 1995; Molinete er al., 1993). This is not present in any other ligase
enzymes, and is not required for ligation itself, but has been found to facilitate specific
recognition and binding of the enzyme to SSBs, possibly displacing PARP-1. This allows
ligation of the break, and therefore removalof the damage (Caldecott et al., 1996).
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Figure 1.1 Repair of single strand breaks (SSBs) created either directly or indirectly by base
excision repair (BER). (1) A DNAsingle strand break (SSB) with damagedendsis created by
hydrolysis of the sugar-phosphate backbone. (2) Poly(ADP-ribose) polymerase 1 (PARP-1)
recognises the SSB,bindsto it and recruits the XRCC1-DNAligase Ila (Lig3a) complex.
(3) The end-processing enzymes AP endonuclease 1 (APE1) and polynucleotide kinase
(PNK)are recruited to repair the damaged ends, producing conventional 5' phosphate and 3'
hydroxyl groups. (4) DNA polymerase B (pol-f) carries out gap-filling by inserting a single
nucleotide into the gap. (5) The nick is sealed by Lig3a, thus completing repair. (6) A
damaged nucleoside is recognised by a specific DNA glycosylase enzyme (G), which cleaves
it to produce an apurinic or apyrimidinic (AP) site. (7) APE1 binds to the APsite and cleaves
the sugar-phosphate backbone, leaving a 5’ deoxyribose phosphate (dRP) group. (8) APE1
recruits pol-f, whichfills in the gap and removes the 5' dRP group toallowligation.
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1.2.2 Alkyl transferases
Although the BER pathway has an importantrole in the repair of various types of DNA base
alkylation and other damage, some alkylation lesions can be directly repaired by damage
reversal. O°-methylguanine generally accounts for less than 8% of total DNA alkylation
(Beranek, 1990) but is particularly relevant since it has the strongest mutagenic potential. If
left unrepaired, O°-methylguanine may mispair with thymine during the DNAreplication
phase ofthe cell cycle. In the following DNA replication cycle this then pairs with adenine,
thus producing a GC-—AT transition mutation. O°-alkylation lesions such as O°-
methylguanine and O°-ethylguanine can be directly repaired in a one-step transfer reaction
carried out by O°-methylguanine-DNA methyltransferase (MGMT) (Tano ef al., 1990) . This
is a 24 kDa protein which removes O°-alkyl groups by stoichiometric transfer to an internal
cysteine residue in the protein, thus restoring the DNA baseto its original unmodified form.
Certain other alkyl groups can also be transferred to MGMT including those from Or-
methylthymine. Unlike a true enzymicreaction, transfer of an alkyl group to MGMTresults
in its irreversible inactivation andtargets it for ubiquitination and subsequent degradation by
the proteasome (reviewedin Peggef al., 1995; Pegg, 2000).
1.2.3. Nucleotide excision repair (NER)
Nucleotide excision repair (NER) is a DNA excision repair mechanism that functions to
remove large lesions, which distort the DNA double helix, such as U.V.-induced 6,4-
photoproducts, pyrimidine dimers and bulky chemical adducts. In mammaliancells there are
two distinct NER pathways termed global genomic repair (GGR) and transcription coupled
repair (TCR). GGRacts on the entire genome, while TCR acts exclusively on transcribed
DNAstrands andis closely associated with RNA polymerase II. NER involves manyrepair
proteins (Woodef al., 2001) and defects in specific components can cause either Xeroderma
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pigmentosum (XP), Cockayne’s syndrome (CS) or Tricothiodystrophy (TTD). XP patients
suffer from extreme photosensitivity of the skin and a high incidence of skin cancer due to
defects in the NER pathway, which normally functions to remove various types of U.V.-
induced DNA damage. CSpatients have defects specifically in the TCR pathway ofNER and
suffer from various symptoms including physical and mental retardation, neurological
dysfunction and skeletal abnormalities due to an increased level of damage in transcribed
DNA. TTD has somesimilarities to CS and patients suffer from brittle hair and nails, with
some also showing photosensitivity. The precise mechanism ofNER damage recognition and
complex assembly remains unclear, but it is likely to involve the sequential recruitment of
various repair proteins and factors at the site of damage as part of a co-ordinated repair
process to excise a section of ssDNA containing the damage and re-synthesise it using the
complementary strand as a template.
In GGR, most lesions are recognised by a complex of XPC and hHR23B (Sugasawaet ai.,
2001), although some types of U.V.-induced lesions may alternatively be recognised by a
second damage recognition complex comprising DDB1 and DDB2/XPE. In TCR, the CS
proteins CSA and CSBhave role in damage recognition where it causes RNA polymeraseII
stalling during transcription. XPAis also thought to be involved in GGR damage recognition
and although its exact role in this is unclear, it is essential for the formation of the core
incision complex in both pathways (Muef al., 1997). Following damage recognition, XPB
and XPD,both subunits of transcription factor ITH (TFIIH), carry out DNA unwinding by 5'-
3' and 3'-5' helicase activities respectively, which allows access to the damage site (Evansef
al., 1997). Next, XPG makesanincision 3-9 nucleotides away from the damagesite in the 3'
direction (Habrakenef al., 1994) and XPF/ERCC1 makes secondincision 15-25 nucleotides
away in the 5’ direction (Sijbers ef al., 1996). This allows the excision of a 24-32 nucleotide
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fragment of single stranded DNA containing the damage. The remaining strandis transiently
protected by replication protein A (RPA) while gap-filling is carried out by pol 6/e in a
processthat also involves the RFC-PCNA complex. Since the complementary strand is used
as a template, this is an example oferror-free repair. Finally, the gap is sealed by Lig], thus
completing the repair process.
1.2.4 Photoreactivation
Photoreactivation is a mechanism to repair pyrimidine dimers, which occur when two
consecutive thymine or cytosine bases on the same DNA strand become covalently linked.
These lesions are induced by exposure to U.V.light and result in a distortion to the DNA
double helix. Removal of pyrimidine dimers can be carried out by photolyase enzymes,
which bind to these sites and carry out direct repair. Photolyases contain two non-covalently
linked flavin adenine dinucleotide (FAD)light harvesting co-factors and require visible light
to complete their reaction mechanism. This involves reduced FADH acting as an electron
donor to break the pyrimine dimerandrestore the bases to their unmodified state (reviewed
by Sancar, 1994). Since all known photolyases are found only in bacteria and fungi, they are
unlikely to be relevant to DNA repair in mammaliancells.
1.2.5 Mismatch repair (MMR)
The DNA mismatch repair pathway functions to remove base mismatchesthat can occuras a
result of DNA polymerase errors during replication. Such mismatches can also occur as a
result of base deamination, oxidation or methylation. The repair mechanisminvolvesinitial
recognition of the mismatch by the heterodimeric MutSa complex consisting of the MSH2
and MSH6proteins (Fishel ef al., 1993; Palombo ef al., 1995). Upon binding thelesion,
MutSa associates with MutLa, a second heterodimeric complex comprising the MLH1 and
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PMS2proteins (Li & Modrich, 1995). In the case of mismatches caused by DNA polymerase
error, the nascentstrand is identified by the presence of an un-ligated nick which is bound by
the RFC-PCNA complex (Kadyrov et al., 2006). PMS2 then introduces a second nick on the
opposite side of the damage site and excision of the strand containing the incorrect base is
carried out by exonuclease I (Genschel efal., 2002). Finally, the strand is re-synthesised by
pol- 6 and the break is sealed by Lig] (Longley ef al., 1997).
1.2.6 Double strand break repair
DNAdouble strand breaks (DSBs) are far more cytotoxic to cells than SSBs and canlead to
dangerous genetic re-arrangements and/or cell death. The two primary pathways for the
removal of DSBs include non-homologous end-joining (NHEJ) and homologous
recombination repair (HRR).
NHEJligates two ends of a DNA DSBtogether without the need for substantial sequence
homology. Since it can sometimes lead to the loss of nucleotides at the site of repair, it is
considered an error-prone mechanism. The first stage of NHEJ involves the binding of the
Ku70/Ku80 heterodimer to both ends of the DSB, which protects them from exonuclease
digestion (Jeggo et al., 1992). This heterodimer then associates with DNA-dependentprotein
kinase catalytic subunit (DNA-PK,s) to form a holoenzyme, which is activated upon contact
with the DNA break (Gottlieb & Jackson, 1993). Activated DNA-PK,; phosphorylates a
number of proteins including various factors involved in DSB end-processing, such as the
MRN complex (consisting of MRE11-Rad50-NBS1) (Maser ef al., 1997). The break is
ligated by Lig4 (Lee ef al., 2003), which forms a constitutive complex with the scaffold
protein XRCC4,essential for the stability of Lig4 in vivo (Bryansef al., 1999).
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The second major method of DNA DSBrepair is homologous recombination repair (HRR).
Unlike NHEJ, the damaged DNA molecule must enter into physical contact with a
homologous, undamaged double strand DNA molecule, which is used as a template for
repair. This makes HRR an important meansoferror-free DBS repair, butrestricts it to the
late S and G2 phasesofthe cell cycle (Johnson & Jasin, 2000). The mechanism involves an
initial processing stage carried out by the MRN complex (consisting of MRE11, Rad50 and
NBS1)to produce 3' single strand overhangs, which become bound by Rad52 (Trujillo ef al.,
1998; Stasiak ef al., 2000). Interaction of Rad52 with Rad51 induces strand exchange with
the homologous, undamaged DNA molecule and allows subsequent DNA synthesis using the
complementary strand of the other molecule as a template (Shen ef al., 1996; Gupta ef al.,
1998). The structure formedis called a Holliday junction andis later resolved to separate the
two homologous DNA molecules (Holliday ef al., 1964; Constaninouef al., 2001). A number
of other proteins are involved in the process of HRR, namely Rad51B, Rad51C, Rad51D,
XRCC2 and XRCC3 (Schild et al., 2000; Massonet al., 2001; Liuef al., 2002; Wieseet al.,
2002).
1.3. Cell division and the DNA damagecheckpoint
The cell cycle is the process by which cell division takes place and hasa four distinct phases.
During the G; (gap 1) phase, cells increase in size and prepare for DNAreplication, which
then occurs during the S (DNA synthesis) phase. The G» (gap 2) phase is another period of
cell growth and preparation involving the synthesis of various cellular components that are
required for division. Cell division itself then takes place in the M (mitosis) phase, whenthe
cell separates its chromosomesinto two separate nuclei and divides to produce twoidentical
daughtercells.
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It is essential that cell division is tightly controlled and does not occur if the cell has not
received the appropriate growth signals, has no space to grow into, has not reached an
adequate size or if its DNA is damaged. Checkpoints are control mechanisms by whichcell
cycle progression can berestricted by preventing certain events from occurring until various
pre-requisites have been satisfied. One such checkpoint is the DNA damage checkpoint,
which prevents or halts the cell division cycle in the presence of DNA damage. This is
extremely importantsince if replication occurs using a damaged DNA template, a mutationis
likely to occur and a daughtercell will inherit an altered copy of the genome. Such mutations
are often lethal to individual cells and are a particular problem in multicellular organisms,
where mutation of certain genes can lead to a susceptibility to cancer. The DNA damage
checkpoint has a number of components including the G1/S component, which can prevent
the cell from entering the S-phase and the G2/M component, which canstop the cell entering
mitosis. The third part of the DNA damage checkpointis the intra-S phase component, which
can interrupt DNA replication when damageis detected, thus allowing repair to occur before
replication continues. Considerable evidence has accumulated which suggests that the
dinucleoside polyphosphate diadenosine 5 '5'"-P' P*-tetraphosphate (ApsA) mayplay role
in this replication stalling, particularly where DNA SSBsare detected.
24
1.4 Diadenosine 5',5'"-P',P*-tetraphosphate (Ap4A)
1.4.1 Introduction to Ap4sA and other dinucleotides
Diadenosine 5',5'"-P',P*-tetraphosphate (Ap4A) wasfirst discovered in 1966 as a product of
the back reaction of amino acid activation during protein synthesis (Zamecnik ef al., 1966;
Randerath et al., 1966). It is one memberof a family of dinucleoside polyphosphates, all of
which consist of two nucleosides linked together by a polyphosphate bridge attached to the 5’
carbon of each (reviewed in McLennan, 2000). In the case of ApsA,the structure consists of
two adenosine nucleosides, linked 5'-5' by four phosphate groups (Fig. 1.2). Other
dinucleotides have similar structures to Ap4A andinclude both homodinucleotides (eg. ApsA,
GpsG) and heterodinucleotides (eg. ApsG, ApsC), varying both in terms of the number of
phosphate groupspresent (from 2 to 7) and the nature of the nucleosides. The most abundant
examples have at least one adenosine moiety in the structure and Ap4A is thought to be the
most common.
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Figure 1.2 Chemical structure of diadenosine 5',5'"-P' P*-tetraphosphate (Ap,A).
In mammalian cells, the intracellular concentration of ApsA is typically 0.05-1 uM during
normalcellular growth (Garrison & Barnes, 1992). There have been conflicting reports on
how these levels may change during the cell cycle with one piece of evidence claiming a
transient 1000-fold increase in Ap4sA at the G1/S boundary (Weinmann-Dorschef al., 1984)
and another claiming a 50-fold decrease just prior to S-phase (Morioka & Shimada, 1985).
However, other investigations have found no significant change in Ap4sA levels throughout
the cell cycle in mammalian cells (Morisef al., 1987; Perret ef al., 1990).
1.4.2 Synthesis of ApsA
Several sources of intracellular ApyA have been identified, the principal one of whichis
thought to be synthesis by aminoacyl-tRNA synthetases (Plateau & Blanquet, 1992). These
enzymesnormally catalyse the aminoacylation of tRNA molecules, which functions to couple
them to their corresponding amino acids, therefore activating the amino acid for use in
protein synthesis. This process proceeds by the following 2 step reaction
(1) Enzyme + amino acid + ATP <>  Enzyme-aminoacyl-AMP + Pyrophosphate (PP;)
(2) Enzyme-aminoacyl-AMP +tRNA — Enzyme + AMP + aminoacyl tRNA
Reaction (1) is freely reversible. However, in the presence of pyrophosphatase (PPase),
which degrades pyrophosphate and prevents the reversal of the reaction (1), and in the
absence of tRNA, some aminoacyl-tRNA synthetases catalyse the synthesis of Ap4sA
(Zamecnik ef al., 1966). This occurs through the addition of adenylate to an ATP molecule
instead of PP; or a tRNA -:
Enzyme-aminoacyl-AMP + ATP — Enzyme + amino acid + ApyA
Further studies have since determined that the synthesis of Ap4sA is actually a more general
process that is carried out by various ligases and transferases (Sillero & Giinther Sillero,
2000). In each case, this involves the enzyme catalysing the transfer of one nucleotidyl
moiety to another, via the formation of an enzyme-oracyl- nucleotidyl intermediate and with
the release of pyrophosphate-:
(1) Enzyme + ATP — Enzyme-AMP+ Pyrophosphate (PP})
(2) Enzyme-AMP+ ATP -— Enzyme + ApsA
Various other dinucleoside polyphosphates are produced in similar mechanismsthat involve
the addition of adenylate to other acceptor nucleotides besides ATP. Two common examples
are the production of Ap3A and Ap4G through the addition of an AMP moiety to ADP and
GTPrespectively (Sillero & Giinther Sillero, 2000). Some specific enzymes found to produce
Ap,A are firefly luciferase, which synthesises Ap4sA in vitro and also in vivo when the
luciferase gene is transfected into mammalian cells (Murphy & McLennan, 2004), acyl-CoA
synthetases (Fontes ef al., 1998) and DNA ligases such as T4 DNAligase (Madrid efal.,
1998). One specific mammalian DNA ligase enzyme found to produce Ap4A is human Lig3a
(McLennan, 2000), which has an important role in the repair of DNA SSBs following
damage(Caldecott et al., 1996).
1.4.3. Degradation of ApsA
In addition to the rate of synthesis, the intracellular concentration of Ap4A is also determined
by its rate of degradation (Guranowski, 2000). Asit is effectively an ATP analogue,if the
level of ApyA becameexcessive, it could inhibit various essential enzyme activities including
protein kinases (Levy ef al. 1983), potentially even becoming lethal to the cell. Therefore,it
is important that Ap,A is not allowed to accumulate andthat its synthesis by various enzymes
is balanced by hydrolysis. While it is likely that some ApsA is degraded through the non-
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specific hydrolytic activity of various nucleotide pyrophosphate family enzymes, there are
also several specific hydrolytic enzymesthat are presumedto play a keyrole in the regulation
of intracellular ApyA (Guranowski, 2000). One such enzyme is human Nudix-type hydrolase
2 (NUDT2), a 17 kDa enzyme which is a member of the Nudix superfamily of proteins
(Thorne et al., 1995) and which hydrolyses ApyA asymmetrically to produce AMP and ATP.
The Nudix superfamily is widespread among eukaryotes, bacteria, archaea and viruses and
consists mainly of pyrophosphohydrolases that act upon substrates of the general structure
nucleoside diphosphate linked to another moiety, X (NDPX), to yield NMP plus P-X
(McLennan, 2006). ApsA hydrolase has also been foundto be active on ApsA and Ap¢A, but
shows no hydrolytic activity towards Ap3A (Lazewska ef al., 1993). Other members of the
Nudix protein family that display a level of specificity for Ap4sA are the diphosphoinositol
polyphosphate phosphohydrolases (DIPPs, e.g. NUDT3, NUDT4, NUDT10 and NUDT11)
(McLennan, 2006). These 19 kDa enzymeshavea relatively low level of hydrolytic activity
on ApsA as a substrate, but a considerably higher activity towards ApsA and Ap¢A,possibly
due to the greater negative charge of these molecules (Safrany ef al., 1999; Leslie ef al.,
2002). As their name suggests they also hydrolyse the unrelated diphosphoinositol
polyphosphates. In addition to Nudix family proteins, another enzyme that hydrolyses ApsA
in vitro is Fragile histidine triad protein (Fhit), a memberof the HIT superfamily encoded by
the FHIT tumour suppressor gene. However, its preferred substrate is Ap3A and it appears
that its hydrolytic activity is limited to this in vivo (Murphyef al., 2000).
1.4.4 Proposed and knownfunctions of ApyA
The precise role of Ap4A andits relative importance to cellular function remains uncertain
but based on a numberof observations, several potential functions have been suggested.
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One possible role for ApsA could be to induce apoptosis under certain conditions in response
to cellular stresses. The level of ApsA has been found to increase in response to various
cellular stresses including hypothermia and heat shock (Baker & Jacobson, 1986) and in
some cases accumulation of Ap4A has been reported to correlate with an accumulation of
apoptotic cells (Vartanian ef al., 1997). Furthermore when certain cell types were
permeabilised and treated with 10 uM Ap,4A, apoptosis was induced, although this was not
the case inall cell types examined (Vartanian ef al., 1999). When a hydrolysis resistant ApyA
analogue was used instead of Ap,A itself, apoptosis did not occur suggesting that Ap4A is
hydrolysed at somepoint in the pathway. One suggestion for a protein that maycarry outthis
function is glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (McLennan,2000), since it
is already known to bind ApsA (Baxi & Vishwanatha, 1995) and also has a known
involvement in the apoptotic process (Sawa ef al., 1997; Tajima ef al., 1999; Sen et al.,
2008).
An alternative role proposed for ApsA is as a second messenger to mediate the release of
insulin from pancreatic B cells in response to an increase in extracellular glucose (Ripoll er
al., 1996). This study found that a 70-fold increase in the concentration ofintracellular Ap4A
occurs in B cells following incubation in concentrations ofglucose that induceinsulin release.
In addition, this level of ApyA was found to be an effective inhibitor of the ATP-regulated K*
channels when applied to the intracellular side of membrane patches excised from f cells.
Since these K” channels regulate the release of insulin, it could be the case that Ap4A has a
role in mediatinginsulin release from f cells in response to increased glucoseoutside thecell.
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As an analogue of ATP, it has been reported that ApsA may also be involved in inhibiting
various enzymes in vivo including adenylate kinase (Purich & Fromm, 1972) or various
protein kinases (Levyef al., 1983), thus playing role in the regulation of their activity.
One of the most recent and most interesting suggestions for a function for intracellular ApsA
is as a transcriptional activator with a role in regulating gene expression in response to
various stimuli (Yannay-Cohen ef al., 2009). The high-affinity IgE receptor (FceRI) is a
tetrameric receptor complex constitutively expressed on the surface of immune system mast
cells. Following FceRI-mediated aggregation of these cells, the MAPK (mitogen activated
protein kinase) signalling cascade is activated which ultimately leads to an allergic response.
It has been found that the level of intracellular Ap4A is increased during mastcell activation
and this appears to be specifically synthesised by lysyl-tRNA synthetase (LysRS), an
aminoacyl-tRNA synthetase that forms part of the multisynthetase complex (MSC) (Lee &
Razin, 2005). Specific phosphorylation of LysRS at serine 207 is required for ApsA
synthesis, and this also causes it to be released from the MSC (Yannay-Cohenefal., 2009).
In addition, this study also found that LysRSis translocated into the nucleus upon mastcell
activation and this is dependent on the MAPKsignalling cascade. It has also been shownthat
LysRS can bind to microphthalmia transcription factor (MITF) which normally exists in
complex with histidine triad nucleotide binding protein 1 (Hint-1) which negatively regulates
its activity (Lee er al., 2004). Interestingly, Hint-1 has been found to bind Ap4A and this
binding has the effect of releasing it from the complex and enabling MITFtotranscribe its
target genes. Based on this, a model has been proposed which suggests that mast cell
activation activates the MAPKsignalling cascade, resulting in the phosphorylation of LysRS.
This would release it from the MSC andinduceits translocation into the nucleus where it
would bind to MITF while producing Ap4A in high amounts. This excess ApsA would
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function as a transcriptional activator by binding to Hint-1 and therefore inducing MITF-
dependent gene expression.
ApsA canalso arise extracellularly as a result of its release from the secretory granules of
certain specialised cell types including blood platelets and adrenal chromaffin cells. ApyA
stored in platelet granules is released under certain physiological conditions and has an
antithrombotic role in the cardiovascular system as a potent competitive inhibitor of ADP-
induced platelet aggregation (Liithje ef al., 1985; Chan ef al., 1997). The Ap4A released from
adrenal chromaffin cells has a role in the nervous system as a neurotransmitter and can
activate specific purinoreceptors that control certain Ca** channels in the brain (reviewed in
Pintor ef al., 2000).
However, of all the various functions proposed for ApsA, the one that is of particular
relevance to the proposed study is an involvement in the stalling of DNA replication
following DNA damage and there appears to be considerable evidence to support this
hypothesis.
1.5 Ap4A and the DNA damageresponse
1.5.1 Increases in Ap,A in response to DNA damage
The first piece of evidence suggesting a role for ApyA in the DNA damage response came
from observations that the intracellular level of ApsA in mammalian cells is increased by up
to 8-fold under various conditions that induce DNA strand breaks (Baker & Ames, 1988).
This study found that treatment of cells with several DNA damaging agents results in an
accumulation of Ap4A, and that the level of this accumulation is generally higher where there
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is a greater incidence of DNA strand breaks. A small increase in Ap4yA (<2-fold) was also
detected after cells were treated with 4-Nitroquinoline 1-oxide (NQO) and U.V., which do
not generally produce strand breaksdirectly, but are primarily bulky lesions repaired by the
nucleotide excision repair (NER) pathway. This increase in Ap4A washigher (4-6-fold) when
cells were pre-treated with cytosine arabinoside (araC), a potent inhibitor of DNA repairthat
results in an accumulation of DNAstrand breaks. Interestingly, ApsA accumulation was not
detected in Xeroderma pigmentosum XP-A cells after the same treatments, and these cells
also did not accumulate strand breaks rapidly following DNA damage due to a defect in
NER, which normally creates SSBs by incision in order to excise various bulky lesions. In
XP variant (XP-V) cells, which are incision repair proficient, the same increases in ApyA
were detected as in wild-type cells. This suggests that the short single strand gaps produced
as NER intermediates result in increased ApyA to a certain extent, although the largest
increases occurred following treatment with agents which cause strand breaks directly and
alkylated base damage whichleadsindirectly to SSBs during BER. Together, these findings
suggested that intracellular ApsA accumulation occurred as a cellular responseparticularly to
the presence of DNA SSBs.
Similar findings were observed in a later study, in which an increase in Ap4sA was detected
following treatment of mammalian cells with the alkylating agent MNNG (Gilson ef al.,
1988). The maximum Ap,A level occurred one hourafter the end of MNNG treatment and
returned to normallevels after approximately 7 hours, suggesting that the Ap4A produced in
response to damage may possibly be used, either directly or indirectly, during subsequent
DNA repair. Interestingly, it was reported that where the cells were treated with 3-
aminobenzamide (3-AB), which is an inhibitor of PARP-1, the increase in ApgA occurred
normally, but then the levels remained continuously stable for the duration of the 3-AB
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incubation. Once PARP-1 inhibition was relieved, the levels of Ap4sA declined, probably
reflecting repair of SSBs and possibly suggesting that PARP-1 has somerole in the process
responsible for the removal of ApsA from the cell. PARP-1 is well characterised and has a
known role in the recognition and repair of DNA SSBs(see pg. 10), providing a further
suggestion that Ap4A is in some wayinvolved with the cellular response to SSBs.
1.5.2. ADP-ribosylation of ApsA by PARP-1
A further link between Ap,A andthe activity of PARP-1 in SSB recognition and processing
comes fromthe finding that, in addition to various proteins, ApsA can actually act as an
acceptor for ADP-ribose in a poly(ADP-ribose) polymerase reaction (Yoshihara & Tanaka,
1981). The product of this reaction was found to be both mono and poly(ADP-ribosylated)
Ap4A, the bound poly(ADP-ribose) elongating at one end of the product during the reaction
(Fig. 1.3). Furthermore, it has been reported that poly(ADP-ribosylated) Ap4A acts as an
efficient inhibitor of in vitro replication of simian virus 40 (SV40) DNA, which has been
extensively studied as a model system for eukaryotic DNA replication (Baker ef al., 1987).
The inhibitory effect is eliminated either by the addition of enzymes that degrade Ap4A,or
those that degrade poly(ADP-ribose), suggesting both components must be intact for
inhibition to occur. It also appears to be specific to Ap4sA, with no inhibition of DNA
replication occurring when Gp4G wasusedin its place. These findings suggest that Ap4sA and
its ADP-ribosylated derivatives may bepart of a novel and as yet uninvestigated mechanism
to stall DNA replication in vivo in the presence of DNA strand breaks.
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Figure 1.3 Chemical structure of mono ADP-ribosylated Ap4sA, adapted from Yoshihara &
Tanaka, 1981. This structure assumesa 1'-2' linkage between ApsA and ADP-ribose,as is the
case between the individual ADP-ribose units of a poly(ADP-ribose) chain. However, asyet,
this has not been proven.
1.5.3 Synthesis of ApsA by DNAligase IIa (Lig3a)
In addition to its role in the ligation of DNA strands following DNA damage, Lig3a also has
the ability to synthesise Ap4A. This synthesis is inhibited by both ligatable and non-ligatable
DNA (McLennan, 2000). Based on this evidence, it has been suggested that following
recruitment of the XRCC1/pol-B/Lig3a complex to a DNA SSB by PARP-1, Lig3a may be
unable to bind the site of damage immediately due to prior binding of PARP-1, as both
molecules have the same recognition sites and DNA binding domains (Mackeyef al., 1999).
In the absence of DNA inhibition, Lig3a may produce Ap,sA at the site of DNA damage
(McLennan, 2000). This would accountfor the increase in cellular Ap4A following exposure
to DNA damage (Baker & Ames, 1988).
1.5.4 Hydrolysis of ApsA by APTX
The mostrecent piece of evidence implicating a role for Ap4A in DNA repair comes from the
finding that the catalytic HIT domain of APTX is also able to bind and hydrolyse ApsA
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(Kijas ef al., 2006). Through its ApsA hydrolase activity, APTX may be involved in the
regulation of DNA damagerelated ApsA and maybethe factor responsible for the return of
Ap4A levels to normal following the initial sharp rise in response to DNA damage (Gilson ef
al., 1988).
1.5.5 Possible mechanism of Ap,A action through DNA polymerasea (pol-a)
Since ApsA can act as a primer for PARP-1 in vitro, and is indeed preferred over some
protein targets (Yoshihara & Tanaka, 1981), it is entirely possible that it would also be
poly(ADP-ribosylated) by the enzymein vivo. Poly(ADP-ribosylated) Ap4A has already been
shown to be an efficient inhibitor of SV40 DNAreplication (Baker ef al., 1987) so its
production in vivo may function to stall DNA replication, allowing time for the break to be
repaired.
There are manypossibilities for the mechanism of action of poly(ADP-ribosylated) Ap4A in
stalling DNA replication and one such mechanism could be the binding of poly(ADP-
ribosylated) ApsA to a protein target required for DNAreplication. This is likely to have the
same effect as direct poly(ADP-ribosylation), imparting a large negative charge on the
protein and inducing its dissociation from DNA. A possible advantage of this overdirect
ADP-ribosylation of the protein would be that poly(ADP-ribosylated) ApsA could diffuse
beyond the initial region of its production and inhibit replicon activity elsewhere in the
nucleus as part of a more global response to DNA damage. One potential target for
poly(ADP-ribosylated) ApsA could be DNA polymerase-a/primase, since a number of
studies have reported links between Ap4A and this complex (Grummtef al., 1979; Baril er
al., 1983: Rapaport & Feldman, 1984; Baxiet al., 1994).
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DNA polymerase-a/primase (pol-a) plays a pivotal role in the initiation of DNAreplication
in eukaryotic cells and is an essential component of the cellular replicative apparatus.
Inhibitors of pol-a. have been shown to inhibit DNA synthesis both in vitro and in vivo (Loeb
et al., 1986) and pol-a/primase activity is essential for initiation of DNA synthesis on single-
stranded DNAtemplates. Due to the discontinuousnature of lagging strand DNAreplication,
continued pol-a/primase activity at the replication fork is required for replication fork
progression along the DNA template. In addition to the core structure of 4 subunits, various
co-factors of DNA pol-a have been purified, some of which have been found to improve the
efficiency of the complex.
In HeLa cells, an ApyA binding protein has been characterised which appears to partially
regulate the activity of a multiprotein form of pol-a (Baril ef al., 1983). It has been
determined that this protein is a heterodimer consisting of 45 kDa and 22 kDa subunits,
designated as Al and A2 respectively (Baxi ef al., 1994). The bindingactivity is localised to
the Al subunit and appears to be specific to ApsA, although some other dinucleoside
polyphosphates do compete for binding with Ap4A to a certain degree. This binding appears
to require the presence of at least one adenosine nucleotide since Ap4G is able to compete
with Ap4A for binding, whereas Gp4G is not (Baxi ef al., 1994). The identity of this pol-a
associated Ap,A binding protein remains unknown,butit could be the target via which ApsA
and/or ADP-ribosylated Ap4A contributes to the stalling of DNA replication in response to
DNAdamage (McLennan,2000).
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1.6 Proposed model for Ap,A involvement in the DNA damage response
Based on the various observations reported so far, a model has been proposed for the
mechanism by which Ap4A might contribute to the slowing of DNA replication during S-
phase in responseto the presence of certain types of DNA damage (McLennan, 2000). Inthis
model (Fig. 1.4), the transient binding of PARP-1 to SSBs prevents Lig3a from binding to
the damage site whenit is initially recruited by the interaction of activated PARP-1 with the
XRCC1-Lig3a complex. Underthese conditions, Lig3a would rapidly produce ApsA, which
would then be ADP-ribosylated by PARP-1. This ADP-ribosylated Ap4sA could diffuse
throughout the nucleus and bind to pol-a complexes, inhibiting pol-a activity by preventing it
from properly binding to DNA dueto the negative charge it imparts. This would slow DNA
replication by stopping the initiation of new replication forks and by preventing lagging
strand priming events during ongoing DNAreplication. This mechanism would form a novel
part of the intra-S phase DNA damagecheckpoint to slow DNAreplication to allow time for
DNArepair to occur.
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Figure 1.4 Proposed model for ApsA involvementin intra-S phase checkpoint control from
McLennan, 2000. (A) A simplified replication fork with DNA polymerase-a/primase (pol-a)
initiating a lagging strand DNA fragment while a single strand break (SSB) is generated
ahead ofthe fork. (B) Poly(ADPribose) polymerase 1 (PARP-1) binds to the SSB and forms
a complex with DNA polymerase-f (pol-B), XRCC1 and DNAligase III (Lig3a). Unable to
bind DNA immediately, Lig3a synthesises ApsA, which acts as a primer for ADP-
ribosylation by PARP-1. The ADP-ribosylated Ap4A then binds to the ApsA-binding site on
the protein associated with pol-a and inhibits it, possibly by reducing its interaction with
DNA. ADPribosylated ApsA also diffuses throughout the nucleus and inhibits other
replication forks in the same way. (C) Auto-ADP-ribosylation of PARP-1 reducesits affinity
for DNA andallowspol-f and Lig3a to bind to the DNA andcarry out the repair process.
1.7 Project aims
The aim ofthis project is to further investigate the possible role of Ap4A in the DNA damage
response. As discussed above, there are various pieces of evidence that taken together
provide a strong suggestion that ApsA is in some way involved in DNArepair. The model
above provides an initial hypothesis which will be tested in various ways using a range of
cells and techniques. This project aims to conclusively determine whether or not ApsA does
have a role in the DNA damageresponse and to probe the exact molecular details of this
involvement.
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CHAPTER2
Materials and Methods
2.1. Materials
2.1.1 Cell lines
AASis a parental wild-type cell line derived from Chinese hamster ovary (Thompsonef al.,
1980a).
EM9 is an AA8-derived XRCC/ mutant, originally isolated by its hypersensitivity to
ethylmethanesulphonate (EMS). It carries the premature termination mutation Q221X in the
XRCCI gene and as result, fails to express functional XRCC1 (Thompson ef al., 1980b;
Thompsonef al., 1990; Shenef al., 1998).
EM7 is an AA8-derived XRCC/ mutant, originally isolated by its hypersensitivity to
ethylmethanesulphonate (EMS). It carries a point mutation in thefirst intron of the YRCC/
gene which prevents normal splicing from occurring. As a result, the cells fail to express
functional XRCC1 (Thompsonef al., 1980; Thompsonefal., 1990; Shenet al., 1998).
H9T3-7-1 is derived from the XRCC1-deficient CHO cell line EM9 (see above) by
transfection with the pH9T3-7 cosmid containing YRCC/ cDNA.Asa result, expression of
XRCC1 is restored (Thompsonef al., 1990).
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CHO-K1is a parental wild-type cell line derived from Chinese hamster ovary (Kao & Puck,
1968).
XR-1 is a CHO-K1-derived YRCC4 mutant, originally isolated by its hypersensitivity to X-
rays (Stamato ef al., 1983; Li et al., 1995)
A549-pS1is a strain of the human lungepithelial cell line A549 which has been transfected
with an empty copy of the constitutive pS expression vector(Iles ef al., 2007).
A549-pSCS5is a strain of the human lung epithelial cell line A549 which has been stably
transfected with the constitutive pS expression vector containing a sequence which produces
human APLF-targeting siRNA molecules. Asa result, these cells are constitutively depleted
of cellular APLF(Iles ef al., 2007).
FD105 M20is a humanskin fibroblastic cell line cell line derived from a patient with ataxia
with oculomotor apraxia type 1 (AOA1) and immortalised by constitutive over-expression of
humantelomerase reverse transcriptase (hTERT). Thesecells carry the premature termination
mutation W279X in the APTXgeneandas result, fail to express APTX protein (Clements e¢
al., 2004).
FD105 M21 is derived from the APTX-deficient cell line FD105 M20 (see above) by
transfection with full length human APTX cDNA under the control of a constitutive
expression promoter. As a result, stable expression of APTX has been restored (El-Khamisy
et al., 2009).
4]
HeLais an immortal human cell line derived from cervical adenocarcinomacells (Scherere¢
al., 1951).
HEK-293 is derived from human embryonic kidney cells which have been immortalised by
adenovirus transformation (Graham & Smiley, 1977).
XrcecI”” mouse embryonic fibroblast (MEF) cells are derived from homozygous Xrecl
mouse embryos, in which both copies of the Xrcc1 gene have been disrupted by targeted
insertion of a DNA fragment containing a premature stop codon. Asa result, these cells fail
to express functional XRCC1 (Tebbsef al., 1999).
XrcecI** MEFcells are derived from homozygous Xrcc1*" mouse embryos, in which both
copies of the Xrcc/ gene are functional. These cells express XRCC1 normally (Tebbs er ai.,
1999).
Cell lines were kindly provided as follows-:
AA8, EM9, CHO-K1, XR-1 and HeLa from Dr. N.J. Jones, University of Liverpool, UK.
HEK-293 from Prof. A.G. McLennan, University of Liverpool, UK.
EM7 and H9T3-7-1 from Dr. L.H. Thompson, Lawrence Livermore National Laboratory,
CA, USA.
A549-pS1, A549-pSC5, FD105 M20, FD105 M21, Xrec/”* MEFs and XrecI"" MEFs from
Prof. K.W. Caldecott, University of Sussex, UK.
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2.1.2 Recombinantproteins
APTX and XRCC1were provided by Prof. K.W. Caldecott, University of Sussex, UK.
NUDT2wasprovided by Prof. A.G. McLennan, University of Liverpool, UK (Swarbrick er
al., 2005).
2.1.3 Primary antibodies
Anti-NUDT2rabbit polyclonal antibody (Hankin et al., 1995) was provided by Prof. A.G.
McLennan, University of Liverpool, UK.
Anti-XRCCIrabbit polyclonal antibody was obtained from Abcam (ID: ab9147)
2.1.4 Constructs
Human NUDT2 cDNA,cloned into the pOTB7 vector, was obtained from the I.M.A.G.E.
consortium (ID: 3623134).
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2.2. Methods
2.2.1 Cell culture and maintenance
Cell growth conditions: With the exception of human AOA]fibroblasts, all cells were
routinely maintained in Dulbecco’s modified Eagle’s media (DMEM,Lonza), supplemented
with 10% (v/v) foetal calf serum (Autogene-Bioclear), 1% (v/v) non-essential amino acids
(Lonza) and 100 pg/mL penicillin-streptomycin (Lonza). Human AOAI fibroblasts were
maintained in minimum essential medium (MEM, Lonza), supplemented with 15% (v/v)
foetal calf serum, 1% (v/v) non-essential aminoacids and 0.3 1g/mL puromycin (Lonza). All
cells were grownin an incubator at 37 °C under a 5% (v/v) CO/air mix.
Subculturing: Trypsinisation was performed as cells approached confluence using 0.12%
(w/v) trypsin with 0.008% (w/v) EDTA,following a brief wash with Hank’s Balanced Salt
Solution (HBSS, Lonza). The trypsin was quenchedbyaddition of an equal volume of culture
medium,after which the cells were centrifuged for 5 min at 500 x g to form pellet and then
re-suspended in fresh culture medium. Approximately 1 x 10° cells were returned to the flask
each time.
Cell storage: Stocks of all cell lines were stored in 1 mL aliquots at -196 °C under liquid
nitrogen. To freeze down, approximately 1 x 10° cells were re-suspended in 1 mL HBSS
containing 10% (v/v) dimethylsulphoxide (DMSO,Sigma-Aldrich) and transferred to a 2 mL
cryogenic tube. This was then cooled gradually to -80 °C in a cell freezer containing
isopropanol and transferred to liquid nitrogen the following day. To recover frozencells, the
cryogenic tube was removed from liquid nitrogen and thawed in a water bath at 37 °C. The
contents were then added to 5 mL culture medium andcentrifuged for 5 min at 500 x g, after
whichthe pellet was re-suspendedin fresh medium andtransferred to a flask.
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2.2.2 Treatmentof cells with DNA damaging agents
Cells were treated with ethyl methanesulphonate (EMS, Sigma-Aldrich) by direct addition of
the liquid to serum-free growth medium. Cell monolayers were extracted for analysis 4 h
after the addition of EMS. Cells treated with cytosine arabinoside (araC, Sigma-Aldrich)
were pre-incubated in 200 uM ofthe nucleoside for 1 h prior to EMStreatmentby addition of
concentrated stock solution (20 mM) to the medium. In these cases, araC remained in the
medium until monolayers were extracted.
2.2.3 Nucleotide extraction and assay
Nucleotide extraction and Ap3A/Ap4A assays werecarried out using a technique based on the
procedure previously published by Fisher & McLennan, 2008. For each determination, six 90
mm dishes of cells were grown to about 80% confluence. Cells were counted in two dishes,
while the remaining four were used for nucleotide extraction and subsequent Ap4A or Ap3A
assay as described below.
Nucleotide extraction: Cell layers were washed briefly with 4 mL of warm (37 °C) PBS,
which was rapidly removed and the dishes were placed onan ice-cold tray. Three mL ofice-
cold 0.4 M trichloroacetic acid (TCA) was addedto each of the dishes and cells were scraped
into a chilled glass tube onice. Each dish wasrinsed with two 1 mL portions of TCA, and the
combined 5 mLextract was left at 4 °C for 15 min. Five mL of 0.6 M tri-n-octylamine in
1,1,2-trichlorotrifluoroethane was added, the tube was shaken for 5 min to neutralise the TCA
and then centrifuged at 500 x g for 5 min. A 4.4 mL portion of the upper aqueous layer was
removed, mixed with 110 wL of 2 M Tris-HCl, pH8.5, 0.2 M magnesium acetate, and 10 units
shrimp alkaline phosphatase (Roche) and incubated for 1 h at 37 °C to hydrolyse mono-
nucleotides. Next, 100 uL of a 50% (v/v) DEAE-Sephacel (Sigma-Aldrich) suspension in 20
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mM Tris-HCl, pH7.6 was added to adsorb the remaining nucleotides. Following 10 min of
intermittent shaking, the suspension was centrifuged for 1 min at 12,000 x g and the
supernatant was discarded. The pellet was washed with three 1.5 mL portions of water and
then shaken for 5 min with 0.5 mL of 1.0 M triethylammonium bicarbonate (pH7.5) to elute
the dinucleotides. After centrifugation for 1 min, the supernatant was removed, the elution
was repeated in the same manner, and the combined supernatants were vacuum-dried at 70 °C
for 2 h.
ApsA assay: Nucleotide extracts were prepared as described above and the vacuum-dried
samples were re-dissolved in 100 uwL assay buffer (25 mM HEPES-NaOH, pH7.8, 5 mM
magnesium acetate). Ten units of alkaline phosphatase were added and the tubes were
incubated for 30 min at 37 °C to hydrolyse any residual ATP, followed by 15 min at 65 °C to
inactivate the alkaline phosphatase. Two 50 uL samples were assayed from each tubebyfirst
placing in a 3 mL tube along with 21 pL water and adding 50 wL BacTiter-Glo reagent
(Promega), which contains a mixture of luciferase enzyme and its substrate luciferin.
Luciferase hydrolyses luciferin in an ATP-dependent reaction, forming oxyluciferin and
producing luminescence proportional to the amount of ATP in the reaction. The tube was
placed in a luminometer at 25 °C (BioOrbit 1250) attached to a chart recorder and the initial
luminescence recorded as a measure of the background level of ATP. Finally 225 ng of
recombinant human NUDT2 enzyme was added, which hydrolyses ApyA asymmetrically
producing one molecule of ATP for each molecule of Ap4A. Luminescence was measured a
second time, giving a measure of the combined level of ATP and Ap4A.For each experiment,
three standards containing a known amount of Ap4A were also measured and used to convert
the level of luminescence to the amount of Ap4A in the samples.
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Ap3A assay: Nucleotide extracts were prepared as described above and the vacuum-dried
samples were re-dissolved in 100 pL assay buffer (25 mM HEPES-NaOH, pH7.8, 5 mM
magnesiumacetate). Ten units of alkaline phosphatase and 225 ng of recombinant human
NUDT2 were added and then the tubes were incubated for 30 min at 37 °C to eliminate
residual ATP and Ap4A, followed by 15 min at 65 °C to inactivate the alkaline phosphatase
and NUDT2. Two 50 wL samples were assayed from each tube byfirst placing in a 3 mL
tube along with 18 uL of 25 mM phosphoenolpyruvate (PEP, Sigma-Aldrich) and 5 pg
pyruvate kinase (Roche) and adding 50 wL BacTiter-Glo reagent. Pyruvate kinase catalyses
the formation of a single ATP molecule from each molecule of ADP in the reaction mix by
the transfer of a phosphate group from PEP. The tube wasplaced in a luminometer at 25 °C
(BioOrbit 1250) attached to a chart recorder and the level of luminescence was recorded as a
measure of the background level of ATP and ADP. Two hundred ng of recombinant human
NUDT2 enzymewasthen added and luminescence measured a second time, to ensure thatall
Ap4sA had been removedin the pre-incubation. Finally, recombinant human Fhit protein, a
specific Ap3A hydrolase (Fisher & McLennan, 2008), was added, which hydrolyses Ap3A
asymmetrically, producing a single molecule each of ADP and AMP for each molecule of
Ap3A. Neither of these two products are directly detected by the luciferase reaction, but the
presence of PEP and pyruvate kinase in the reaction converts ADP to ATP whichis detected
by the assay. Luminescence was measured final time, giving a measure of the combined
level of both the background ATP/ADP/ApsA and Ap3A. For each experiment, three
standards containing a known amount of Ap3A were also measured and used to convert the
measure of luminescenceto the amount of Ap3A in the samples.
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2.2.4 siRNA knockdown of XRCC1 in HeLacells
Human XRCC1-targetting siRNA (ID:17841, Table 2.1) was purchased from Ambion and
the lyophilised RNA wasre-suspended in RNase-free water to a concentration of 10 pmol/L
and stored at -80 °C until use. For siRNA knockdown, HeLa cells were seeded into a 6-well
plate with 2 mL antibiotic-free growth medium in each well and then incubated until
achieving 50% confluence. Prior to transfection, 300 pmol of siRNA and 5 ul of
lipofectamine (Invitrogen) were each added to separate 250 uL aliquots of OptiMEM-1
medium(Invitrogen), mixed and left at room temperature for 5 min. The two aliquots were
then combined, mixed and left at room temperature for a further 20 min to allow
siRNA/lipofectamine complex formation. Five hundred tL of the mixture was then added to
each well and cells were incubated overnight, after which the medium wasreplaced with
normal growth medium. When cells became confluent, they were trypsinised and transferred
to 90 mm tissue culture dishes. Cells were extracted for the analysis of XRCC1 expression or
Ap4A level on reaching 70% confluency, normally 3-4 days following the original
transfection with siRNA.
Table 2.1 Sequence of annealed siRNA molecule with 3' overhanging TT dinucleotides(tt)
used for knockdown of XRCC1 expression in human cells. siRNA was purchased from
Ambion.
 siRNA Sequence
Anti-XRCC1 5' -GGAAGAUAUAGACAUUGAGtt-3’ — sense sequence
ID: 17841 3' -ttCCUUCUAUAUCUGUAACUC-5' — antisense sequence
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2.2.5 Ap4sA hydrolase enzyme activity assay of recombinant proteins
Purified recombinant proteins (100 ng NUDT2, 100 ng XRCC1 or 150 ng APTX) were
incubated at 25 °C in a total reaction volume of 100 uL containing 70 mM HEPES-NaOH,
pH7.8, 10 mM MgClandeither 10 uM ApsA substrate (for NUDT2 and XRCC1) or 100
uM ApsA substrate (for APTX). The tube was immediately placed in a luminometer at 25 °C
(BioOrbit 1250) attached to a chart recorder and the linear increase in luminescence over an
initial time period of approximately 10 min was recorded as a measure of the rate of ATP
production by hydrolysis of the substrate. To measure ApsA phosphorylase activity,
phosphate was also present in the reaction at a final concentration of 5 mM. To measure
possible symmetrical hydrolysis of ApsA, phosphoenolpyruvate (PEP) was addedto a final
concentration of 5 mM along with pyruvate kinase (Roche) to a final concentration of 50
ng/mL in order to convert any ADP product to ATP, which is detected by the assay. Atleast
two determinations were madein all cases.
2.2.6 Treatment of cells with DNA ligase inhibitors
The DNA ligase inhibitors L67 and L82 were obtained from ChemDiv (San Diego, CA,
USA). Concentrated stock solutions (5 mM) were prepared in DMSOandstored at -20 °C.
Cells were treated with 50 uM ofeither L67 or L82 by direct addition of the stock solution to
the growth medium. An equal volume of DMSO wasadded to untreated cells as a control.
Cell monolayers were extracted for ApsA analysis 18 h after addition.
2.2.7. Analysis of cell extracts by high performanceliquid chromatography (HPLC)
For chromatographic analysis, eight 90 mm dishes of cells were grown to 70% confluence
and nucleotides were extracted as described previously (pg. 45-46). Following extraction, the
vacuum-dried samples were re-suspended in 30 uL of 1.0 M triethylammoniumbicarbonate
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(pH7.5), combined into a single tube and vacuum-dried again at 70 °C for 2 h. The sample
was then re-suspended in 21 mM ammoniumbicarbonate, pH9.6, and applied to a MonoQ
column (GE Healthcare), equilibrated with 21 mM ammonium bicarbonate, pH9.6.
Nucleotides were eluted with a linear gradient of ionic strength achieved by increasing
concentration of ammonium bicarbonate, pH9.6, between 21 mM and 0.7M overa total
volume of 20 mL. Samples were collected in 0.5 mL fractions at a flow rate of 1 mL/min.
Fractions were vacuum-dried at 70 °C for 2 h, re-suspended in 0.5 mL water and then
vacuum-dried again at 70 °C for 2 h. Finally, samples were re-suspended in 50 pL ApsA
assay buffer (25 mM HEPES-NaOH, pH7.8, 5 mM magnesium acetate) and assayed for
ApsAas described previously (pg. 46).
2.2.8 Synthesis of ADP-ribosylated Ap4A in vitro
Synthesis of ADP-ribosylated ApsA in vitro was carried out based on the procedure
published by Tanakaet al., 1981. A total reaction volume of 50 pL was used containing 25
mM Tris-HCl, pH8.0, 1 mM DTT, 100 uM ApyA, 25 pM NAD‘, 5 ug histone H1
(Calbiochem), 10 ng PARP active DNA (R&D Systems) and 20 pg recombinant PARP-1-
HSA (high specific activity) enzyme (Trevigen). PARP active DNA is a sample of dsDNA
fragments containing single-strand nicks that specifically bind to PARP-1, thusactivating its
catalytic activity. Reactions were incubated at 25 °C for 18 h and then the enzyme was
deactivated by incubating for 10 min at 95 °C and centrifuging for 10 min at 9,000 x g. The
supernatant was removed andstored until further analysis.
2.2.9 Treatmentof cell extracts with poly(ADPribose) glycohydrolase
Nucleotide extracts were prepared from untreated EM9cells and then incubated at 37 °C for
18 h in total reaction volume of 100 pL containing 25 mM Tris-HCl, pH8.0, 10 mM B-
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mercaptoethanol (Sigma-Aldrich) and 10 ug recombinant poly(ADPribose) glycohydrolase
(PARG) enzyme(Enzo Life Sciences). Following incubation, the enzyme was deactivated by
incubating for 10 min at 95 °C and centrifuging for 10 min at 9,000 x g, after which the
supernatant was removedandstored until further analysis.
2.2.10 Treatment of cells with PARP-1 inhibitor
The PARP-1 inhibitor NU1025 was obtained from Sigma-Aldrich. A concentrated stock
solution (5 mg/mL) wasprepared in DMSOandstored at -20 °C. Cells were treated with 100
uM of NU1025 by direct addition of the stock solution to the growth medium. An equal
volume of DMSO was addedto untreated cells as a control. Cell monolayers were extracted
for analysis 18 h after addition.
2.2.11 Molecular cloning of NUDT2 cDNA
Amplification of plasmid DNA and miniprep: Bacterial cells carrying pOTB7 plasmid
DNAwere amplified by inoculating 3 mL Luria-Bertani (LB) medium containing 100 pg/mL
ampicillin and incubating for 18 h at 37 °C in shaker set to 225 rpm. Plasmid DNA was
subsequently extracted using a QIAGEN miniprep extraction kit.
Polymerase chain reaction (PCR): PCR amplification of human NUDT2 cDNA was
performed using 50 wL Bioline 2X BioMix'™ (Tag DNA polymerase, 2 mM dNTPs, 32 mM
(NH4)2SOq, 4 mM MgCl, 125 mM Tris-HCl (pH8.8), 0.02% (v/v) Tween-20), 0.5 ug of each
primer (Sigma-Aldrich), 1 mg template DNA and deionised water up to a total reaction
volume of 100 uL. Cycling conditions were as follows: 1 cycle at 94 °C for 1 min followed
by 35 cycles at 94 °C for 1 min, 54 °C for 1 min, 72 °C for 30s, and final extension 72 °C for
5 min. PCR products werepurified using a QIAquick PCRpurification kit (QIAGEN).
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Restriction digests: Restriction digests were carried out using restriction enzymes supplied
by Promega. A total reaction volume of 20 uL was used consisting of 2 uL enzyme buffer (6
mM Tris-HCl, pH7.5, 50 mM NaCl, 6 mM MgCl, 1 mM DTT), 5 units of each enzyme, | pg
DNAand deionised water. The reaction was incubated at 37 °C for 4 h, after which the
restriction enzymes were inactivated by heating to 65 °C for 15 min. The digested products
were then purified using the QIAquick PCRpurification kit (QIAGEN).
Agarosegel electrophoresis: Electrophoresis of DNA fragments wascarried out using a 50
mL gel containing 1% (w/v) agarose dissolved in TAE (Tris-Acetic acid-EDTA) buffer (40
mM Tris-HCl, pH8.0, 1 mM EDTA and 0.1% (v/v) acetic acid), with ethidium bromide
added to a final concentration of 0.5 ug/mL prior to pouring. DNA fragments for separation
were mixed with loading gel (Sigma-Aldrich) and the gel was run in TAE buffer at 100V for
1 h, after which the DNA fragments were visualised in a UV transilluminator (Alpha
Innotech).
Ligation: Ligation was carried out using T4 DNA ligase supplied by Promega. A total
reaction volume of 10 yL was used consisting of 1 pL ligase buffer (300 mM Tris-HCl,
pH7.8, 100 mM MgCh, 100 mM DTT, 10 mM ATP), | unit ligase, 100 ng vector DNA, 20
ng insert DNA and deionised water. The reaction was incubated at 15 °C for 16 h to allow
ligation to occur.
Transformation and blue-white screening: For transformation, 5 L of the ligation mix
was added to 100 ,1L of competent E. coli cells, and the mixture left on ice for 30 min. Cells
were heat-shocked at 42 °C for 90 s and placed onice for a further 2 min. Nine hundred pL
of super-optimal catabolite-repression medium was then added andthecells incubated at 37
52
°C while being shaken at 225 rpm for | h. Following incubation, 200 wL of the cell
suspension was plated out on each of four Luria-Bertani (LB) agar plates containing 100
ug/mL ampicillin (Sigma-Aldrich), 40 wg/mL  5-bromo-4-chloro-3-indolyl B-D-
galactopyranoside (X-Gal, Sigma-Aldrich) and 0.2 mM isopropyl  £-D-1-
thiogalactopyranoside (IPTG, Sigma-Aldrich). Plates were incubated for 18 h at 37 °C to
allow colony formation. Colonies containing the correct ligation product were identified by
their lack of blue colouring. Plasmid DNA was subsequently extracted using a miniprep
extraction kit (QIAGEN).
DNA Sequencing: The NUDT2 cDNA sequence cloned into the pNEBR-X1Hygro vector
was sequenced using the BigDye sequencing method and ABI 3100 genetic analyzer
(Applied Biosystems), according to the protocol given by the manufacturer and using the
sequencing primers supplied with the vector.
DNAprecipitation: To precipitate DNA, 0.1 volumes of 3M sodium acetate and 2.5
volumes of ice-cold 100% (v/v) ethanol were added to the sample, which was then stored
overnight at -18 °C. Following centrifugation at 12,000 x g for 15 min, the supernatant was
discarded and the pellet washed with 70% (v/v) ethanol. The pellet was air-dried and re-
suspendedin the appropriate buffer or sterile deionised water and stored at -18 °C.
DNA quantification: DNA was quantified by measuring the absorbanceofthe solution using
a nanodrop ND-1000 spectrophotometer (Nanodrop Technologies, USA), according to the
instructions provided by the manufacturer.
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2.2.12 Transfection
For transfection, a 75 cm? culture flask was seeded with ~2 x 10°cells in their normal growth
medium and incubated overnight. Prior to transfection, 1 ug of vector DNA and 50 pl of
lipofectamine (Invitrogen) were each added to separate 1.5 mL aliquots of OptiMEM-1
medium (Invitrogen), mixed well and left at room temperature for 30 min. The twoaliquots
were then combined, mixed well and left for a further 15 min at room temperature to allow
DNA/lipofectamine complex formation, after which a further 3 mL of fresh OptiMEM
medium was added. The cells were drained of medium, washed in HBSS and the
DNA/lipofectamine/OptiMEM mixture was added. The cells were then incubated for 5 h,
after which the medium was removed, the cells washed in HBSS and fresh normal growth
mediumadded. The cells were then incubated overnight under normal conditions. Following
the transfection procedure, cells were harvested and a portion of them spread at 200, 500,
5,000 and 10,000 cells/dish in 500 g/ul G418 or 500 wg/ul hygromycin for ten days. In order
to determine transfection frequency, dishes were fixed and stained with methylene blue for 1
h, after which they were rinsed, air-dried and the surviving colonies counted. From other
dishes, 25 colonies were picked in order to obtain cell populations derived from single
colonies. Successfully transfected cells containing the plasmid were cultured in medium
containing 500 pg/mL G418 or 500 pg/mL hygromycin in order to maintain selective
pressure.
2.2.13 Luciferase reporter gene expression assay
For transient transfection with pNEBR-X1GLuc, cells of each clone were seeded in their
normal growth medium into 2 wells each of a 24-well plate and incubated until reaching
~60% confluence. Prior to transfection, 9.6 ug of the pNEBR-X1GLuc plasmid and 36 yl of
TransPass™ D2 transfection reagent (NEB) were added to 2.4 mL serum-free DMEM
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(Lonza) and mixed gently. The mixture wasleft at room temperature for 30 min, after which
100 wL was addedto each well, and the cells were returned to the incubator for 1 h. For each
clone, 10 uL of RSL1 (500 uM in DMSO) wasadded to one well (final conc. 500 nM) to
induce luciferase gene expression, while 10 uL DMSO was added to the other well as a
negative control. Cells were incubated for a further 18 h, after which a 20 pL sample of
medium was taken and assayed for luciferase activity using the reagents and protocol
provided in the kit. Briefly, a working solution of GLuc substrate was produced by diluting
20 uL substrate to a total volume of 2 mL with GLuc assay buffer. For each 20 uL sample,
50 pL of GLuc working solution was added, mixed well and the level of luminescence was
promptly measured in a luminometer (BioOrbit 1250) at 25 °C.
2.2.14 Immunoblotting
Cells were grown to near-confluence, harvested and washed twice with HBSS.Cells were
then lysed with protein extraction buffer (50 mM Tris-HCl, pH6.8, 10% (w/v) sodium
dodecyl sulphate (SDS), 10% (w/v) EDTA, 5% (v/v) glycerol, 5% (v/v) B-mercaptethanol)
and the lysate boiled for 10 min. Following centrifugation for 10 min at 9,000 x g, the
supernatant was subjected to SDS polyacrylamide gel electrophoresis with an acrylamide
concentration of 7.5% (w/v). Following separation, proteins were transferred to a Hybond™
nitrocellulose membrane (GE Healthcare) using a submerged transfer apparatus (Wolf labs)
filled with 20 mM Tris base, 150 mM glycine and 20% (v/v) methanolat a constant current
of 350 mA for 4 h. After blocking for 1 h with 5% (w/v) non-fat dried milk in Tris-buffered
saline (TBS, 50 mM Tris-HCl, pH8.8, 150 mM NaCl, 1% (v/v) Tween 20), the membrane
was incubated with the primary antibody (1:1000 dilution in TBS) or anti-B-actin antibody
(1:5000dilution in TBS) for 18 h at 4 °C. After washing thoroughly with TBS, the membrane
was incubated with anti-rabbit horseradish peroxidase-linked secondary antibody (GE
a0
Healthcare) (1:1000 dilution in TBS and 5% (w/v) non-fat dried milk) for 2 h, and the
membrane washed thoroughly again with TBS. Proteins were detected by enhanced
chemiluminescence (GE Healthcare), using the protocol and reagents supplied with the kit.
Briefly, equal volumes of luminol and enhancer solutions were added to the membrane,
mixed well and the excess liquid drained away. The membrane wasthen exposed to X-ray
film (GE Healthcare) for 2 h in a hyper cassette before development. Protein size was
determined using Full Range Rainbow (GE Healthcare) molecular weight markers (10-250
kDa).
2.2.15 Ap4A hydrolase activity assay of cell lysates
Cells were grown to near-confluence, harvested and washed twice with phosphate-buffered
saline (PBS). Cells were lysed with a non-denaturing protein extraction buffer (50 mM Tris-
HCl, pH7.6, 150 mM NaCl, 1 % (v/v) Igepal CA-630) and smaller cellular proteins (<50
kDa) were partially purified by centrifugal filtration using Microcon filter columns
(Millipore) to remove any possible contaminating high-molecular-weight nucleotide
pyrophosphatase/phosphodiesterase I activity. Two 10 L samples were assayed from each
extract by adding to a3 mL tube containing 50 uL assay buffer (70 mM Hepes-KOH, pH7.8,
10 mM MgCl), 20 uL ATP monitoring reagent (Lonza) and excess Ap4A substrate (final
concentration 10 1M) in a final volume of 100 pL. The tube was immediately placed in a
luminometer at 25 °C (BioOrbit 1250) attached to a chart recorder and the linear increase in
luminescence overaninitial time period of approximately 10 min wasrecorded as a measure
of the rate of ATP production by hydrolysis of the substrate.
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2.2.16 Clonal survival assays
Sub-confluentcell cultures (in exponential growth) were harvested by trypsinisation, counted
by haemocytometry, diluted to known cell concentrations and plated into 90 mmtissue
culture dishes. Five control dishes were prepared at 200 cells/dish, while those with the
chemical to be added wereprepared in triplicate with increasing cell numbers used at higher
drug doses. For the EMSsurvival assays, dishes were incubated for 4 h to allow attachment
of the cells, after which the medium was removed and attached cells were washed once with
HBSS. Cells were then treated with EMS for 1 h in serum-free medium, which was then
removed and replaced with normal medium. Dishes were incubated for 10 days under normal
growth conditions to allow colony formation. For survival assays to G418 and hygromycin,
dishes were incubated for 2 h after cell plating, after which the chemical was added. Cells
were then incubated for 10 days under normal growth conditions to allow colony formation,
with G418 or hygromycin present for the entire period. In both cases following colony
formation dishes were then fixed and stained with methylene blue for 1 h, after which they
were rinsed, air dried and the colonies counted.
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CHAPTER 3
Intracellular Ap,A is increased in CHO cells under
conditions that cause an accumulation of DNA strand
breaks andspecifically by the absence of XRCC1
3.1 Introduction
As discussed previously (pg. 31-38), there are various pieces of evidencethat, taken together,
suggest that Ap4A is in some wayinvolved in the DNA damage response and/or DNArepair.
The aim of this project is to determine whetherornot this is the case, and if so, to probe the
exact molecular details of this involvement. There are a great manystrategies and techniques
that could potentially be used to achieve this aim and oneparticularly useful tool is likely to
be the extensive collection of well characterised Chinese hamster ovary (CHO) DNArepair
mutant cell lines that are available in the laboratory. Examining cells deficient in various
specific components of DNA repair pathways, and investigating what effect this may have on
cellular ApyA, could provide some important information about the possible biological
function of the molecule. Therefore, it was decided to carry out someinitial experiments to
examine the level of ApsA in CHO cell lines and how this may change undercertain
conditions.
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3.2. Results
3.2.1 CHOcells have a comparablelevel of intracellular Ap4A to humancells
The normalintracellular level of ApsA has previously been reported for a variety of different
cell lines and types, but the level present in the CHOcells that are being usedin this study is
unknown. Initial experiments were carried out to determine the normal background level of
ApsA in the wild-type CHO cell line AA8, in order to compare this with existing data on
Ap,A levels in humancells and to provide a reference point for future work.
To determine the normal basal level of ApsA, nucleotides were extracted from AA§8cells
grown under normalculture conditions and the level of ApyA was measured using a specific
luminometric assay (see pg. 45-46). The data obtained indicates a level of 0.63 + 0.07
pmol/ 10° cells [mean + S.E.M, n=6], which is comparable to the levels previously reported
for various humancell lines (Murphyef a/., 2000). Based on an approximate cell diameter of
12 um for AA8 (Dr. N.J. Jones, personal communication), this equates to an intracellular
Ap4A concentration of around 0.69 uM, which is also consistent with previous reports that
the intracellular ApsA concentrationis usually between 0.05 and 1 uM during normalcellular
growth (Garrison & Barnes, 1992). The fact that the level of intracellular ApsA detected in
AA8cells was within the range already reported for a numberof different humancell lines
further validates the use of CHO cells as a model system and confirmsthe efficiency of the
assay technique.
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3.2.2 Ap4sA is increased in CHO cells following DNA alkylation damage and under
conditions that cause an accumulation of DNAstrand breaks
Previous evidence from humanfibroblastic cells indicates that a 2-8-fold increase in the level
of intracellular ApyA occurs following DNA damage and an accumulation of DNA strand
breaks (Baker & Ames, 1988). To determineif this was also the case in CHOcells, the wild-
type cell line AA8 was treated for 4 h with increasing doses of the DNA alkylating agent
ethyl methanesulphonate (EMS;Fig. 3.1A). EMS induces DNA alkylation damage, primarily
producing N7-ethylguanine, which is removed by the BER pathway. Following EMS
treatment, the level of ApyA was found to be increased by up to 2.1-fold at the maximum
concentration (Fig. 3.2) and analysis of the data using a paired t-test indicated that this
observed increase in ApsA wasstatistically significant (P=0.041).
Previous reports suggest that the increase in intracellular ApsA observed following DNA
damage is caused specifically by an accumulation of DNA strand breaks with the highest
levels of ApsA correlating with the greatest incidence of DNAstrand breaks (Baker & Ames,
1988). DNA strand breaksare caused indirectly by alkylating agents such as EMSand occur
during the incision stage of the BER process, in which the DNAstrand is nicked by APE] to
allow excision of the damaged nucleotide. Since this is part of a co-ordinated process, it is
likely that the steady-state level of strand-breaks remains limited regardless of the level of
DNA base damage, since an equilibrium may be reached in which DNA strand breaks are
continually sealed at a rate equal to which new incisions are made.If this were the case, it
would be expected that specific inhibition of gap-filling and re-sealing during BER would
produce a muchhigherlevel of Ap4A since breaks would then be allowed to accumulate.
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To test this hypothesis in AA8, cells were treated with EMS following a pre-incubation with
cytosine arabinoside (araC; Fig. 3.1B). This nucleotide analogue prevents re-synthesis and
gap-filling during the BER process, but since the incision stage is not affected, DNA strand
breaks will accumulate in cells throughout the EMS treatment. As expected, under these
conditions, the level of Ap4A increased considerably, reaching a maximum of ~14-fold
higher than the basal level (Fig. 3.2) and analysis of the data using a paired t-test indicated
that this increase in Ap4A wasstatistically significant (P=0.021). Therefore, this data supports
existing evidence that ApsA is increased under conditions that cause an accumulation of
DNAstrand breaks.
wo OR
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Figure 3.1 (A) Chemical structure of ethyl methanesulphonate (EMS). (B) Chemical
structure of cytosine arabinoside (araC).
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Figure 3.2 Increase in intracellular ApsA in the wild-type CHOcell line AA8 in response to
treatment with increasing doses of ethyl methanesulphonate (EMS). Cells were treated with
EMSin serum free medium for 4 h, both in the presence (blue circles) and absence (red
squares) of 200 uM cytosine arabinoside (araC) and then intracellular Ap,sA was immediately
extracted and assayed. Each data point represents the mean of three independent
determinations and the error bars represent the S.E.M. Someerror bars are smaller than the
marker size and are therefore notvisible in the figure.
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3.2.3 The XRCC1-deficient CHO cell line EM9hasa very high level of ApsA
Although there is evidence that the level of Ap4A is increased by treatment of cells with
various agents that induce different types of DNA damage (Baker & Ames, 1988; Gilson ef
al., 1988), it appears that the largest increases in ApsA occur in response to the types of
damage that are specifically repaired by the SSBR and BER pathways. Based on this
observation, it was decided to examine the level of ApsA in cells that are deficient in these
processes to determine whateffect this may have.
The CHO cell line EM9 is an AA8-derived YRCC/ mutant, which wasoriginally isolated by
its hypersensitivity to EMS (Thompsonet al., 1980b). It has since been determined that EM9
carries the premature termination mutation Q221X in the YRCC/ geneandasa result, fails to
express functional XRCC1 (Thompson ef al., 1990; Shen ef al., 1998). As discussed
previously (pg. 11-13), XRCC1 is a scaffold protein that co-ordinates the processes of SSBR
and BER through multiple interactions with a number of different repair enzymes. Cells
deficient in XRCC1 are defective in these processes and consequently have a reducedability
to repair DNA damage and are hypersensitive to DNA alkylating agents such as EMS.
Examination of the intracellular level of ApsA in EM9cells revealed a very striking increase
when compared to the parental wild-type strain AA8, with a 16-fold higher level of ApyA
detected (Table 3.2). Interestingly, in response to EMS treatment, a decrease in Ap4sA
occurred after a dose of 20 mM,which contrasts with the increase in Ap4sA observed in wild-
type AA8cells following the same treatment (Table 3.1, Fig. 3.3). This may possibly be due
to a higherrate of cell death for EM9cells under the treatment conditions, since they are 21-
fold more sensitive to EMS than AA8 (Thompsonefal., 1982). However, at a much higher
dose of 200 mM,an increase in ApsA wasrecorded.
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Table 3.1 Change in ApsA levels in the xrcc/cell line EM9 in response to treatment with
increasing doses of ethyl methanesulphonate (EMS). Cells were treated with EMSfor 4 h in
serum free medium andthenintracellular ApsA was immediately extracted and assayed. Each
value is the mean + S.E.M.of independenttriplicate determinations. P values were calculated
using a paired t-test and represent the statistical significance of the observed difference
between the level of Ap4sA in cells following the treatment indicated and that in untreated
cells.
 Dose of EMS Ap4A (pmol/10°cells) Fold difference to P value
(mM) untreated cells
0 12.44 1.32 - -
2 9.86 + 2.42 0.79 0.23
20 6.64 + 1.77 0.54 0.029
200 17.4 + 1.35 1.40 0.035
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Figure 3.3 Change in ApsA levels in the xrccJ° cell line EM9 (red squares) in response to
treatment with increasing doses of ethyl methanesulphonate (EMS). Cells were treated with
EMSfor 4 h in serum free medium andthen intracellular ApsA was immediately extracted
and assayed. Data for the wild-type cell line AA8 is also shown for comparison (bluecircles).
Each data point represents the mean of three independent determinations and the error bars
represent the S.E.M. Someerror bars are smaller than the marker size and are therefore not
visible in the figure.
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3.2.4 Increased ApsA appears to be specifically associated with a lack of XRCC1 in
CHOcells
Following on from the observations made above which indicate a 16-fold higher level of
ApsA in the XRCC1-deficient cell line EM9, it was decided to next examine the level of
Ap4A in a second XRCC1-deficient cell line. This is important to provide confirmation that
the elevated level of Ap4sA in EM9is specifically associated with the lack of XRCC1, and not
simply a result of some other unknown changein the cells which may have been induced by
the mutagenesis process or occurred randomly during prolonged growth of the cell line in
culture.
EM7 is an independent AA8-derived XRCC/ mutant, which was also isolated by its
hypersensitivity to EMS (Thompsonef al., 1980). The specific mutationis different than that
in EM9cells, in this case being a point mutation in the first intron of the YRCC/ gene, which
prevents normal splicing from occurring. Howeverthe result of this is that like EM9,cells
fail to express functional XRCC1 (Thompsoner al., 1990; Shen et al., 1998). Examination of
the level of ApsA in EM7revealed that it was also elevated significantly compared to the
parental strain AA8, and was comparable to the very high levels detected previously in EM9
cells (Table 3.2). This suggests that this effect is specifically associated with the lack of
XRCC1 in both cases.
To provide further confirmation of this, the level of Ap4sA wasalso measured in H9T3-7-1
cells, which are derived from EM9 bytransfection with full-length human XRCC/ cDNA,
thus restoring XRCC1 expression. These cells are proficient in DNA repair and show
correction of their mutant phenotype with respect to sensitivity to DNA damaging agents
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(Thompsonef a/., 1990). In these cells, intracellular ApsA was found to have beenrestored to
levels comparable to the wild-type strain AA8 (Table 3.2).
Immediately following these measurements of Ap4sA levels, an XRCC1 immunoblot was
carried out on the fourcell lines, which confirmed that XRCC1 expression wasas expected in
each case (Fig. 3.4). Taken together, the data reported here indicate a normal low level of
ApsA in the parental wild-type strain and a high level in the two independent AA8-derived
mutant strains EM7 and EM9, both of which fail to express XRCC1. Where XRCC1
expression is restored in EM9 bytransfection with human XRCC/ cDNA,the level of ApyA
is restored to levels comparable to the wild-type strain AA8 (Fig. 3.4, Table 3.2). These
findings appearto indicate that the substantial increase in the level of ApyA in CHOcellsis
specifically associated with the lack of XRCC1 protein.
Table 3.2 Increased intracellular ApsA in XRCC1-deficient Chinese hamster ovary (CHO)
cells. AA8 is a wild-type CHOcell line while EM7 and EM9 are independent AA8-derived
XRCCI mutant strains which lack functional XRCC1. H9T3-7-1 is derived from EM9 and
has been complemented with YRCC] cDNA, thus restoring XRCC1 expression. Cell
monolayers were extracted and analysed for intracellular Ap4A using a specific luminometric
assay. Each value is the mean + S.E.M.with the numberof independent determinations(77)in
brackets. P values were calculated using an unpaired t-test and represent the statistical
significance of the observed difference between the level of Ap4A in each cell line compared
to that in AA8.
 Cell line ApsA (pmol/10° cells) Fold difference to P value
AA8
AA8 0.63 + 0.07 (n=6) - -
EM7 8.77 + 0.84 (n=3) 13.9 0.0002
EM9 9.96 + 1.65 (n=6) 15.8 <0.0001
H9T3-7-1 0.78 + 0.06 (n=4) 1.24 0.17
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Figure 3.4 Detection of XRCC1 expression in CHO cells by immunoblotting. Wholecell
extracts were prepared fromthecell lines indicated andcellular proteins were immunoblotted
with an anti-XRCC1 antibody. The wild-type cell line AA8 (lane 1) shows normal expression
of XRCC1 while the xrcc/° mutant cell lines EM7 (lane 2) and EM9 (lane 3) show no
expression. Expression of XRCC1is restored in EM9cells transfected with human XRCC/
cDNA(lane 4). B-actin was detectedinall cell lines as a loading control.
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3.2.5 Mouse XRCC1 knockoutcells also have an elevated level of ApsA
Based on the data above from CHOcells, it appears that the normal background level of
intracellular Ap4A is significantly increased by the specific lack of XRCC1 protein. However,
since no measurements had been madein othercell types lacking XRCC1, it was not known
if this is also the casein other speciesor is simply an effect limited to CHO cells.
Theavailability of an Xrcc1“ mouse embryonic fibroblast (MEF) cell line in which XRCC1
has been stably knocked out (Tebbs et al., 1999) provided an excellent opportunity to also
investigate the effect of a lack of XRCC1 onthe level of Ap4A in mouse cells. The wild-type
cell line Xrecl*™* expresses XRCC1 normally and provided an appropriate control strain.
Examination of the normal background level of Ap4A in each ofthese cell lines determined
that the XRCC1 knockout cells have a 5.3-fold increased level of Ap4A in comparison with
cells which express XRCC1 normally (Table 3.3). This appears to indicate that the lack of
XRCC1 also producesan increase in the level of intracellular ApgA in mousecells as well as
CHOcells.
Table 3.3 Increased intracellular ApsA in mouse embryonic fibroblast (MEF) cells in the
absence of XRCC1. Xrccl”is a stable XRCC1-knockoutcell line, while Xrcc]”” is the
control strain that expresses XRCC1 normally. Cell monolayers were extracted and analysed
for intracellular Ap4A using a specific luminometric assay. Each value is the mean + S.E.M.
of four independent determinations. The P value was calculated using an unpairedt-test and
represents thestatistical significance of the observed difference between the level of Ap4A in
the twocell lines.
 Cell line ApsA (pmol/10° cells) Fold difference P valueXrecl™ 0.04 + 0.01 - -Xrecl™ 0.21 + 0.07 5.3 0.047
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3.2.6 siRNA knockdown of XRCC1 in the humancell line HeLa appearsnotto alter
the backgroundlevel of ApyA
Having established that the normal basal level of intracellular ApsA appears to be
substantially increased by the lack of XRCC1 in both CHO and MEFcells, it was next
decided to examine if this might also be the case in human cells. Unfortunately, no stable
XRCC1-deficient human cell lines were available, so it was instead decided to suppress
XRCCI1 levels using siRNA technology in order to determine the effect that this has on the
level of ApsA. Efficient siRNA knockdown of XRCC1 in the human cell line HeLa has
already been reported (Fan ef al., 2007), and this produced a cellular phenotype similar to
EM9in terms of a reduced level of DNA ligase IIa and an increased sensitivity to DNA
alkylating agents. Therefore, it seemed possible that XRCC1 knockdown mayalso result in
an increased level of ApsA, consistent with what was observed in EM9cells.
The procedure used was based on that previously used by Fan ef al., 2007, and utilised the
same XRCC1-targetting siRNA sequence that was successfully used in that study (Materials
and Methods, Table 2.1). Four days following siRNA transfection, an XRCC1 immunoblot
was carried out on both transfected and untransfected HeLa cells, which confirmed that
expression of XRCC1 had been successfully reduced, with no detectable protein present in
the knockdowncells (Fig. 3.5). However, surprisingly, this knockdown of XRCC1 appeared
have no effect the level of Ap4A, (Table 3.4), which contrasts with what might be expected
given the observations made previously in XRCC1-deficient rodent cells (Table 3.2, Table
3.3). To confirm that this was not an effect specific to HeLa cells, the same experiment was
repeated using a different humancell line HEK-293 and again, no detectable decrease in the
level of ApsA wasrecorded.
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Table 3.4 Effect of siRNA knockdown of XRCC1 on the level of intracellular ApsA in
humancell lines. Thecell lines indicated were transfected with XRCC1-targetting siRNA and
after 4 days, cell monolayers were extracted and analysed for intracellular ApsA using a
specific luminometric assay. Each value is the mean of independent duplicate determinations.
 Cell line and treatment ApsA (pmol/ 10° cells)
HeLa 0.30
HeLa + siRNA 0.30
HEK-293 0.20
HEK-293 + siRNA 0.21
1A 1B 2A 2B
xRCC1 —>  
HeLa HeLa + HEK-293 + HEK-293
siRNA siRNA
Figure 3.5 Detection of XRCC1 expression in human cells following protein down-
regulation by siRNA.Cells were transfected with XRCC1-targetting siRNA and after 4 days,
whole cell extracts were prepared from the cell lines indicated and cellular proteins were
immunoblotted with an anti-XRCC1 antibody. Untransfected HeLa (lane 1A) and HEK-293
(lane 2B) show normal expression of XRCC1 while expression is not detectable in siRNA
transfected HeLa (lane 1B) or HEK-293 (lane 2A).
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3.2.7. Lack of XRCC1appearsto havenoeffect on the level of Ap3A in CHOcells
Asdiscussed previously (pg. 25), other dinucleotides in addition to Ap4A also existin cells at
varying concentrations. One such dinucleotide is Ap3A, of whichthe level has been reported
to vary from almost undetectable levels to around 2.4 pmol/ 10° cells depending on FHIT
status (see below). Since the level of ApsA appears to be substantially elevated in XRCC1-
deficientcells, it was decided to examineif this effect was specific to Ap4A,or if the level of
Ap3A wasalso altered by the presence or absence of XRCC1.
Examination of the level of Ap3A in the wild-type cell line AA8 and the AA8-derived xrecI”
mutant EM9 revealed no significant difference in Ap3A between the two cell lines (Table
3.5), suggesting that the presence or absence of XRCC1 has noeffect on intracellular Ap3A.
However, it is noteworthy that the level of Ap3A detected in both cases is relatively high
compared with the values reported for other cells (McLennan & Murphy, 1999; Murphy er
al., 2000).
Previous findings have indicatedthat the level of Ap3A is regulated by Fragile histidine triad
protein (Fhit), an Ap3A hydrolase encoded by the FHIT tumoursuppressor gene.In cells that
have high Fhit expression, the level of Ap3A is very low and often undetectable, whereas in
Fhit negative cells including many tumourtissues and othercell lines, the level of Ap3A is
much higher. The high level of Ap3A detected in both AA8 and EM9cells strongly suggests
that at some point they have lost Fhit expression, which is not surprising given the length of
time they have been grownin culture and the apparentinstability of the fragile site containing
the FHIT gene (Huebner & Croce, 2003).
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Table 3.5 Effect of the lack of XRCC1 onthe level of intracellular Ap3A in CHOcell lines.
AA8is a wild-type CHO cell line while EM9 is an AA8-derived XRCC/ mutantstrain that
lacks functional XRCC1. Cell monolayers were extracted and analysed forintracellular Ap3A
using a specific luminometric assay. Each value is the mean + S.E.M. of independent
triplicate determinations. The P value was calculated using an unpaired t-test and represents
the statistical significance of the observed difference between the level of Ap4A in the two
cell lines.
 Cell line Ap3A (pmol/10°cells) Fold difference P value
AA8 3.05 + 0.27 - -
EM9 2.98 + 0.32 0.98 0.76
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3.2.8 Lack of XRCC4 appearsto causes an increase in the level of ApsA in CHO cells
The substantial increase in Ap4A detected in XRCC1-deficient CHOcells raises the question
of whetheror not cells deficient in other DNA repair proteins mayalso have an elevated level
of ApsA. One obvious candidate for investigation is XRCC4, a 38 kDa DNA repair protein
whichis involved in DNA double-strand break (DSB) repair by non-homologousend-joining
(NHEJ). Interestingly, in a manner analogous to XRCC1/Lig3a, XRCC4 forms a tight
complex with DNA ligase IV (Lig4) that stimulates Lig4 and is important for maintaining its
stability in vivo (Bryansef al., 1999).
The CHOcell line XR-1 lacks functional XRCC4 protein due to the complete deletion of the
XRCC4 gene and is therefore deficient in DSB repair by NHEJ (Li et al., 1995). The
intracellular level of Ap4A in XR-1 was foundto be elevated in comparison with the parental
strain CHO-K1 (Table 3.6), although to a much smaller extent than that found in the absence
of XRCC1.
Table 3.6 Increased intracellular ApyA in CHOcells in the absence of XRCC4. CHO-K1is a
wild-type CHOcell line while XR-1 is a CHO-K1-derived mutantstrain deficient in XRCC4
due to the deletion of the XRCC4 gene. Cell monolayers were extracted and analysed for
intracellular ApyA using a specific luminometric assay. Each value is the mean + S.E.M. of
independenttriplicate determinations. The P value wascalculated using an unpaired t-test and
representsthe statistical significance of the observed difference between the level of Ap4A in
the two cell lines.
 Cell line Ap,A (pmol/10° cells) Fold difference P value
CHO-K1 0.62 + 0.08 - -
XR-1 1.73 + 0.20 2.8 0.007
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3.3. Discussion
The 2.1-fold increase in ApyA detected in the wild-type CHO cell line AA8 following
treatment with the DNAalkylating agent EMSis consistent with previous reports of 2-8-fold
increases in Ap4A following treatment of cells with various agents which induce DNA
damage (Baker & Ames, 1988). EMS is a monofunctional alkylating agent that induces
ethylation of DNAbases, primarily producing N7-ethylguanine (~70%) and to a lesser extent
N3-ethyladenine (~10%). These adducts are recognised by DNA glycosylase enzymes such
as alkyladenine DNA glycosylase (AAG) whichinitiates the process of BER by cleaving the
damagedbase to produce an APsite. This is then recognised by AP endonuclease 1 (APE1)
which makes an incision adjacent to the site, allowing excision of the damaged nucleotide
and creating a gap which is subsequently filled in by DNA polymerase B and sealed by DNA
ligase Hla.
Existing evidence has suggestedthat the increase in Ap4A following DNA damageis caused
specifically by an accumulation of DNA strand breaks. In the case of EMStreatment, DNA
strand breaks are produced indirectly by incision repair and since these breaks are
subsequently removed by re-synthesis and ligation,it is likely that the steady-state level of
strand breaks remains limited. Where wild-type cells were treated with EMS in combination
with araC, the Ap4A increase was muchgreater, reaching levels 13-fold higher than untreated
cells (Fig. 3.2). AraC prevents re-synthesis and gap-filling during BER,butsince the incision
stage is not affected, the level of DNA strand breaks will accumulate throughout the
treatment (Hiss & Preston, 1977; Dunn & Regan, 1979). Therefore the findings here support
the existing hypothesis that Ap4A is increased under conditions that cause an accumulation of
DNAsingle strand breaks (Baker & Ames, 1988).
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Possibly the most intriguing observation made here is that the basal level of Ap4A is
increased by up to 16-fold in the AA8-derived XYRCC/ mutant cell lines EM7 and EM9
compared to the parental strain AA8 (Table 3.2). This also appeared to be the case in mouse
Xrccl knockoutcells, albeit to a lesser extent (~5-fold), suggesting that this is not an effect
specific to CHO cells (Table 3.3). This increase in ApsA could simply be producedindirectly
as result of a high background level of DNA strand breaks in XRCC1-deficient cells,
although such a high level did not occur in wild-type cells, even after treatment with very
high doses of EMS/araC to produce an extremely high level of DNA strand breaks.
Therefore, XRCC1 may have a more direct involvement in DNA-damage related ApsA
synthesis and regulation, and may provide a good opportunity to further investigate this.
A numberofpossible explanations for the increase in ApsA in the absence of XRCC1 can be
hypothesised and will be addressed later (Chapter 4), but one such explanation is that
uncomplexed Lig3a produces ApsA as a result of its inability to bind to XRCC1. In the
absence of DNA, Lig3a produces Ap4A in vitro (McLennan, 2005) and since Lig3a usually
exists in complex with XRCC1, which is responsible for localising it to sites of ligation
activity on DNAstrands (Caldecottet al., 1994; Caldecott et al., 1995), Ap4A synthesis may
also occur in vivo in the absence of XRCC1and the resulting lack of Lig3a contact with
DNA.
The fact that no increase in the level of intracellular ApsA was detected in human cells
following siRNA knockdown of XRCC1 is somewhat surprising, and initially appears
inconsistent with the data from CHO and MEFcells. While there is certainly the possibility
that increased ApsA in the absence of XRCC1 is a rodent specific phenomenon, the
unavoidable differences in the experimental strategies mean that this is not necessarily the
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case. In both the CHO and MEF cell lines, expression of functional XRCC1 has been
completely eliminated, whereas in humancells expression has been supressed to some degree
by siRNA, but not eliminated completely. The extent of this XRCC1 suppression was not
quantified here, but was estimated to be in the region of 80% by Fan er al., 2007, using the
same experimental procedure and cells. These authors also reported that the loss of XRCC1
was accompanied by a substantial reduction in the level of DNA ligase IIIa, as might be
expected given the known requirement of XRCC1 for the stability of the enzyme (Caldecott
et al., 1995). XRCC1 is thought to exist normally at approximately 8x10* moleculespercell,
in excess of DNAligase IIa, which is thought to exist at approximately 3x10* molecules per
cell (Leppard ef al., 2003; Dong & Tomkinson, unpublished results). Therefore, it is likely
that the remaining XRCC1 following siRNA down-regulation is sufficient to stabilise a
significant portion (>50%) of DNAligase IIIa, whereas in completely XRCC1-deficientcells
this would not be the case. Given the overall reduction in DNA ligase IIIa levels that also
occurs, it could actually be the case that no uncomplexed enzymeis present to synthesise
Ap4A.It is also possible that uncomplexed human Lig3a is simply too unstable to survive in
vivo. In EM9cells the level of Lig3a is reduced 5-fold dueto its increased rate of degradation
by the proteasome (Moore ef al., 2000), but the remaining Lig3a must certainly be
uncomplexed and may rapidly produce Ap4A as result ofits inability to localise to DNA
and carry out its normal ligation activity. The findings made here do not necessarily mean
that ApsA would notalso be increased in humancells if a full XRCC1 knockout was made.
Anotherinteresting finding madehere is that the XRCC4-deficientcell line XR-1 also has an
elevated level of Ap4sA in comparison with its parental strain CHO-K1. Similar to the
XRCC1/Lig3a complex, XRCC4 forms a tight complex with Lig4, which stabilises the
enzymeandis essential for its normal function in vivo (Li et al., 1995). Although Lig4 has
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not specifically been shownto synthesise Ap4A,it is certainly possible that this may occur in
the absence of DNA or XRCC4,similar to the model proposed above for Lig3a. One notable
difference is that where XRCC1-deficient cells retain around 20% Lig3a activity, Lig4 is
reduced to only around 5% in XRCC4-deficient cells (Bryans ef al., 1999). This could
possibly provide some explanation as to why the increase in Ap4A is much smaller in XR-1
compared to EM7 and EM9.
In summary, a numberofinteresting findings have been made so far which appear to support
a role for Ap4sA in the DNA damage response and provide someinteresting clues as to the
possible mechanism of this involvement. This provides some excellent opportunities to
further investigate the exact details of this involvement in the subsequent stages of this
project.
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CHAPTER4
Possible source and covalent modification of Ap4A by
ADP-ribose
4.1 Introduction
The observations made in the previous chapter demonstrate that the level of intracellular
ApsA is increased in CHOcells in response to treatment with EMS, an agent which induces
alkylated base damage, a type of damage normally repaired by the BER pathway.
Furthermore, the key observation was madethat in cells lacking XRCC1, a protein which
plays a pivotal role in BER, the normal background level of intracellular Ap4A is
substantially elevated by almost 16-fold compared to wild-type cells. This finding both
strengthens the existing evidence supporting a role for Ap4A in the DNA damageresponse,
and provides a good opportunity to further investigate the details of this involvement.
Following on from the observations made in the previous chapter, the primary focus of the
investigation was to determine both the mechanism of this DNA damage-related ApsA
synthesis, andthe possible function that this ApyA may have in the DNA damageresponse.
As discussed previously (pg. 11-13), XRCC1 is a scaffold protein which co-ordinates the
processes of SSBR and BERthroughinteractions with a numberofdifferent repair enzymes.
It forms a tight complex with DNAligase IIIa (Lig3a) (Caldecott ef al., 1994; Caldecott er
al., 1995), which binds to sites of DNA damageandrecruits other repair proteins including
the DNA end-processing enzymes aprataxin (APTX) and polynucleotide kinase (PNK), as
well as DNA polymerase B, which is responsible for DNA gap-filling during repair. Based on
the information available about XRCC1 andits interaction partners, a numberof possible
sourcesfor the increased Ap4A can be hypothesised.
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4.2 Results
4.2.1 XRCC1 hasno detectable ApsA hydrolase activity in vitro
The simplest explanation for the increased level of Ap4A detected in the absence of XRCC1
is that XRCC1 itself has a previously unreported Ap4A hydrolase activity, the loss of which
leads to an increase in intracellular ApsA. This seemed a very unlikely scenario given the
apparent lack of any enzymatic activity in XRCC1, and the lack of any sequence or putative
domain features which may suggest the protein has a nucleotide hydrolase activity. However,
it was important that this possibility be ruled out before further investigation into other
potential sources of the increased Ap4A observed in the absence of XRCC1.
To determine if XRCC1 did have ApsA hydrolase activity, purified recombinant XRCC1 was
directly assayed in vitro, using a specific luminometric enzymeactivity assay, as described
on pg. 49. Although human NUDT2is knownto hydrolyse Ap4A asymmetrically (producing
AMP and ATP products), the possibility also existed that hydrolysis by XRCC1 may be
symmetrical, producing only ADP as a product,as is the case for a numberof other enzymes,
such as the E. coli ApsA hydrolase ApaH (Guranowski, 2000). Therefore, both types of
hydrolysis were investigated and it was found that XRCC1 appeared to have no detectable
ApsA hydrolase activity in vitro (Table 4.1).
4.2.2 XRCC1hasno detectable effect on NUDT2 Ap4A hydrolaseactivity in vitro
Analternative hypothesis for the increased level of Ap4A in the absence of XRCC1is that
XRCC1 stimulates the activity of another ApsA hydrolase, and that the loss of this
stimulation reducesthe activity of that enzyme andresults in elevated levels of Ap4A. Since
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the primary Ap4A hydrolase in mammalian cells is NUDT2 (Guranowski, 2000), this seemed
an obvious potential candidate for investigation.
The normal rate of ApyA hydrolysis by NUDT2 wasfirst determined by direct assay of the
recombinant human protein in vitro. NUDT2 was found to have a very high level of
hydrolytic activity on Ap4A (Table 4.1), and the presence of recombinant XRCC1 at an
equimolar ratio to NUDT2 appearedto have no effect on therate of activity, with only a very
slight decrease recorded. This indicates that the presence of XRCC1 alone does not appear to
have a stimulative effect on the Ap4sA hydrolytic activity of NUDT2 which might have
contributed to the substantially elevated levels of Ap4A in the absence of XRCC1.
Table 4.1 ApsA hydrolase activity of XRCC1in vitro and the effect of XRCC1 on the ApyA
hydrolase activity of NUDT2in vitro. Purified, recombinant proteins (100 ng XRCC1 or 45
ng NUDT2) wereincubated at 25 °Cin total reaction volume of 100 uL containing 70 mM
HEPES-NaOH, pH7.8, 10 mM MgCl, and 10 uM ApsA substrate. To measure possible
asymmetrical hydrolysis of ApsA by XRCC1, phosphoenolpyruvate (PEP) was added to a
final concentration of 5 mM along with pyruvate kinase to a final concentration of 50 ng/mL.
For the NUDT2 + XRCC1 reaction, XRCC1 was added at equimolar ratio to NUDT2. The
rate of ApsA hydrolysis was determined by measuring the rate of ATP product formation
using a specific luminometric assay, as described on pg. 49. Each value is the meanofat least
two determinations.
 Reaction components Specific activity (fmol Ap4sA
hydrolysed/min/pmolprotein)
XRCC1 Nodetectable hydrolysis
XRCC1 + PK + PEP Nodetectable hydrolysis
NUDT2 126
NUDT2 + XRCC1 118
80
4.2.3 The level of intracellular ApsA is increased when DNA ligase IIa is inhibited
from binding its DNA substrate
A more plausible explanation for the increase in ApsA in the absence of XRCC1is that un-
complexed Lig3a produces Ap4A aseither a direct or indirect result of its inability to bind to
XRCC1. Lig3a has already been shown to produce Ap4A in vitro, and importantly, this
reaction is inhibited by both ligatable and non-ligatable DNA (McLennan, 2000). Since
Lig3a usually exists in complex with XRCC1, which is responsible for localising it to sites of
ligation activity on DNAstrands (Caldecott et al., 1994; Caldecott et al., 1995; Cappelli er
al., 1997), it seems entirely possible that ApsA synthesis by Lig3a may be initiated or
increased in the absence of XRCC1, and the resulting lack of Lig3a contact with DNA.
Although XRCC1 is required to maintain the stability of Lig3a in vivo, and in EM9cells the
level of Lig3a is actually reduced 5-fold due to its increased rate of degradation by the
proteasome (Mooreet al., 2000), it could still be the case that the remaining unstable Lig3a,
unable to localise to sites of ligation activity, rapidly produces Ap4A until its degradation
occurs.
To further investigate the hypothesis that Lig3a may produce Ap4A asa result ofits inability
to contact its normal DNA substrate, experiments were carried out using inhibitors which
interfere with the normal function of the enzyme. The DNAligase inhibitor L67 (ChemDiv)
was originally identified using a computer-aided drug design technique to screen a large
database of commercially available low molecular weight compoundsthat were predicted to
bind the DNA-binding pocket of DNA ligase I (Chenet al., 2008). These authors found L67
to be a simple competitive inhibitor, which interacts with the DNA binding domain of both
DNAligase I and III and prevents binding to the correct DNA substrate by both enzymes.
The chemical structure of this molecule is shownin Fig. 4.1A.
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The normal process of DNAligation proceeds by a three step reaction mechanism(Fig. 4.2).
L67 has no detectable effect on the first stage of ligation, which involves the formation of a
covalent DNA ligase-AMP intermediate, and which occurs completely independently of the
DNAsubstrate. The second stage of ligation involves the transfer of the AMP moiety from
the enzymeto the 5' phosphate terminusof the nick, and L67 causes a substantial reduction in
the level at which this occurs due to its interference with the ability of the enzyme to bind the
substrate. The final stage of ligation involves the catalysis of a phosphodiester bond by the
nonadenylated enzyme, which releases AMP. L67 was most potentat inhibiting this stage of
ligation, again by preventing the DNAsubstrate from correctly binding to the DNA binding
pocket of the enzyme (Chenef al., 2008).
Since the effect of L67 is limited to preventing Lig3a from binding to DNA,it does not
prevent the formation of a DNA ligase-AMP intermediate, or presumably the transfer of the
AMPmoiety to an ATP acceptor, thereby producing Ap4A. Indeed, it seemed quite possible
this activity may be increased by the inability of the enzyme to properly contact the DNA
substrate, as appears to be the casein vitro. To test this hypothesis, wild-type AA8 cells were
treated with L67 andthe level of intracellular ApyA was measured and compared to untreated
cells. Following treatment, a 4.8-fold increase in intracellular Ap4A wasdetected (Table 4.2).
Since L67 is active on both DNA ligase I and DNA ligase III, a similar molecule L82
(ChemDiv) wasalso used as a control. L82 affects the same stage of ligation as L67,but is
active on DNA ligase I only, with no detectable effect reported on Lig3. The chemical
structure of this molecule is shown in Fig. 4.1B. Unlike with L67, treatment of AA8 cells
with L82 did not cause a substantial increase in the level of intracellular Ap4sA, suggesting
that the increase in ApsA observed following L67 treatment is most likely to be caused by
DNAligaseIII, rather than DNAligase I
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Figure 4.1 Chemical structures of the DNA ligase inhibitors L67 (A) and L82 (B).
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Figure 4.2 Stages of DNA ligation. (A) DNA ligase reacts with ATP and forms a covalent
ligase-AMPintermediate. (B) the AMPresidue is transferred to the 5’ phosphate terminus of
the DNA nick. (C) The ligase enzymecatalyses the formation of a phosphodiester bond tore-
seal the gap, with the release of AMP.
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Table 4.2 Increase in intracellular ApsA in wild-type CHO cells following treatment with the
DNAligase inhibitor L67. Cells were treated with 50 uM L67 or 50 uM L82 (ChemDiv) by
addition of concentrated stock solutions (5 mM in DMSO)to the growth medium. An equal
volume of DMSO was added to untreated AA8 cells as a control. Cell monolayers were
extracted for analysis 18 h after addition and assayed for Ap4A using a specific luminometric
assay. Each value is the mean of independent duplicate determinations.
 Cell line and treatment Ap4A (pmol/10° cells) Fold difference to
untreated AA8
AA8 0.57 -
AA8 + L67 2.72 4.8
AA8 + L82 0.75 1.3
84
4.2.4 Lack of Aprataxin causesan increasein the level of intracellular ApyA
Another possible explanation for the increased ApsA in XRCC1-deficient cells is that a
reduction in the previously reported ApsA hydrolytic activity of APTX (Kijas ef al., 2006)
may occur whenit is not complexed with XRCC1. APTX normally directly interacts with
CK2-phosphorylated XRCC1 protein and this is required for its recruitment to sites of DNA
damage (Hirano er al., 2007). In addition to its reported roles in DNA end processing during
damagerepair (Ahel ef al., 2006; Takehashi et al., 2007), the central catalytic HIT domain of
aprataxin is also able to bind Ap4A andto utilise it as a substrate, resulting in its hydrolysis
(Kijas et al., 2006). This activity is low when measured in vitro using uncomplexed
aprataxin, although the possibility exists that it may be increased by complex formation with
XRCC1. Indeed, there is already evidence that XRCC1 stimulates the activity of various
other enzymes, including APE1 (Vidal ef al., 2001) and PNK (Whitehouse er al., 2001), the
latter of which binds to the same region of CK2-phosphorylated XRCC1 as APTX, by means
of a similar FHA domain (Clements ef al., 2004; Date et al., 2004). Despite a report that the
presence of triply phosphorylated XRCC1 peptide, which binds to the FHA domain of
APTX,does not appear increase its ApsA hydrolase activity in vitro (Kijas ef al., 2006), it
could be the case that the presence of other components of the XRCC1 complex, and the
participation of APTX inits multiprotein complex doesincrease the activity in vivo.
FD105 M20 is a humanskin fibroblastic cell line derived from a patient with ataxia with
oculomotor apraxia type 1 (AOA1), the autosomal recessive neurological syndromeresulting
from the lack of functional APTX. These cells carry the premature termination mutation
W279X in the APTX gene and as result, fail to express APTX protein (Clements efal.,
2004). FD105 M21 is derived from FD105 and has been complemented with full length
human APTY cDNA underthe control of a constitutive expression promoter, and therefore
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stable expression of APTX has been restored (El-Khamisy ef al., 2009). Together, these two
cell lines provided an opportunity to investigate the effect that the lack of APTX has on the
level of intracellular Ap4A, and to examine the possible role that APTX may have in the
regulation of Ap4A levels in vivo.
The level of intracellular ApsA was determined in both FD105 M20 and FD105 M21 cell
lines using the standard assay technique (Table 4.3). These data indicate that the specific lack
of APTX causes a substantial (5.7-fold) increase in the level of intracellular Ap4yA. This
suggests that despite only a very low level of Ap4sA hydrolase activity reported in vitro,
APTX mayhavea role in the regulation ofits levels in vivo. However, this increased ApsA
could alternatively be simply an indirect effect caused by accumulation of endogenously
generated SSBsin thesecells due to defective SSBR in the absence of APTX.
Table 4.3 Increase in intracellular ApsA caused by the lack of APTX. FD105 M20is an
immortalized human skin fibroblast cell line derived from an AOA patient and deficient in
APTXdue to a premature termination mutation in APTX. FD105 M21 has been corrected by
transfection of full length AP7XY cDNA underthe control of a constitutive expression vector,
thus restoring cellular APTX. Cell monolayers were extracted and analysed forintracellular
Ap4A using a specific luminometric assay. Each value is the mean + S.E.M.of independent
triplicate determinations. The P value was calculated using an unpaired t-test and represents
the statistical significance of the observed difference between the level of Ap4A in the two
cell lines.
 Cell line Ap4A (pmol/10° cells) Fold difference P value
FD105 M21 0.22 + 0.03 - -
FD105 M20 (APTX “) 1.26 + 0.29 Sd 0.031
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4.2.5 Aprataxin has a low level of ApsA hydrolase activity in vitro, and this appears to
be reducedin the presence of DNA
Although only a low level of Ap4A hydrolase activity has been reported in vitro for APTX
(Kijas et al., 2006) it was decided to re-examine this using the more sensitive luminometric
assay described previously (pg. 44-45). Purified, recombinant and catalytically active APTX
wasassayed for Ap,A hydrolase activity in vitro and, consistent with the previousfindings, a
low level of activity was detected (Table 4.4). To further probe the possible effect that
XRCC1 complex formation may have on this activity, full length CK2-phosphorylated
XRCC1 was added to the sample of APTX, and this appeared to produce no significant
change in the subsequent rate of ApsA hydrolysis. The presence of phosphate in the reaction
produced no detectable change in the level of Ap4A hydrolysis either, ruling out the
possibility that APTX wasin fact an ApsA phosphorylase (ApsA + Pi > ATP + ADP), rather
than a hydrolase. Although unlikely for a true HIT protein like APTX, this activity was
recently been reported for one suchprotein isolated from Mycobacterium tuberculosis (Mori
et al., 2010), raising the interesting possibility that the same may have been true for APTX.
Addition of DNA however, did cause a decreasein relative Ap4sA hydrolase activity, both in
the absence and presence of XRCC1.
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Table 4.4 Ap4A hydrolase activity of APTX measured in vitro. A 150 ng sample of purified,
recombinant APTX was incubated at 25 °C in a total reaction volume of 100 wL containing
50 mM HEPES-NaOH,pH7.6, 1 mM MgCland 100 uM ApyAsubstrate. The rate of ApsA
hydrolysis was determined by measuring the rate of ATP product formation using a specific
luminometric assay, as described on pg. 49. Purified recombinant XRCC1 was added at
equimolar ratio to APTX, DNA wasaddedto a final concentration of 0.05 uM and phosphate
was added to a final concentration of 5 mM. Each value is the mean of at least two
determinations.
 Reaction components Specific activity (pmol Ap4sA
hydrolysed/min/pmol APTX)
APTX 5.01 x 10°
APTX + XRCC1 4.70 x 10°
APTX + DNA 2.48 x 10°
APTX + XRCCI + DNA 2.04x 10°
APTX + phosphate 5.02 x 10°
4.2.6 Lack of APLF appears not to cause an increasein the level of intracellular ApyA
APLF (aprataxin and polynucleotide kinase-like factor; also known as PALF and Xip1) is a
DNArepair protein which has been recently identified through the similarity of its FHA
domain to those present in both APTX and PNK(lles et al., 2007). As with these two
proteins, the FHA domain mediates an interaction with phosphorylated XRCC1, and
accumulation of APLF also occurs at sites of DNA strand breaks. Recruitment of APLF to
these sites of DNA damageis mediated by two tandem poly-(ADPribose) bindingzinc finger
(PBZ) domains which bind to poly-(ADPribose) (PAR), present at DNA strand breaks due to
the activity of PARP-1 (Rulten er al., 2008). Depletion of cellular APLF results in a delay to
the repair of DNAsingle strand breaks following ionising radiation and produces a phenotype
resembling that of PARP-1 deficient cells. Given the knowninteraction between XRCC1 and
APLF,the effect of APLF depletion on the levelof intracellular ApyA was also examined.
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A549-pSC5 is a strain of the human lung epithelial cell line A549, which has been stably
transfected with the constitutive expression vector pS, encoding a human APLF siRNA
knockdown sequence whichresults in constitutive depletion of cellular APLF(Iles ef al.,
2007). A549-pS1 is a control A549 cell line which harbours the empty pS vector. To
investigate the possible involvement of APLF in regulating Ap4A levels in vivo, the level of
ApsA was measured in both cell lines (Table 4.5). The lack of any significant difference in
Ap,A between normal cells and those depleted in APLF suggests that this protein does not
immediately appear have a involvement in the regulation of intracellular Ap4A.
Table 4.5 Effect of APLF depletion on the level of intracellular ApsA. A549 pSC5 cells
constitutively express an siRNA knockdownsequence whichresults in depleted APLF, while
A549 pS1 cells carry only the empty expression vector as a control. Cell monolayers were
extracted and analysed for intracellular Ap4A using a specific luminometric assay. Each value
is the mean + S.E.M.of independenttriplicate determinations. The P value was calculated
using an unpairedt-test and representsthestatistical significance of the observed difference
between the level of Ap4A in the twocell lines.
 Cell line ApsA (pmol/10° cells) Fold difference P value
A549 pS1 0.14 + 0.01 - -
A549 pSC5 0.12 + 0.02 0.86 033
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4.2.7. The majority of adenyl dinucleotides in untreated wild-type cells co-elute with an
Ap4A standardfollowing fractionation by HPLC
The luminometric Ap4A assay using NUDT2 detects nucleotides in the form Ap,A, where n
is >4, not only ApsA. To confirm the exact nature of the dinucleotides being detected in these
experiments, high performance liquid chromatography (HPLC) wasusedto fractionate the
cell extracts, and the amount of Ap,A in each fraction was subsequently assayed.
Fractionation of a sample of mixed adenine dinucleotide standards, containing an equal 1 uM
concentration of ApsA, ApsA and ApsA, showed clear separation of the different nucleotides
according to the size of their negative charge (Fig. 4.3), confirming the effectiveness of the
separation technique and conditions used.
Following fractionation of untreated AA8cell extracts, almost all of the material detected by
the ApsA assay co-eluted with the Ap4A standard (Fig. 4.4), indicating that that the majority
of Ap,A that was previously detected in untreated cells was indeed Ap4A. A very low level of
material co-eluted with each of the ApsA and Ap¢A standards, suggesting that as expected,
these dinucleotides only exist at very low levels in untreated cells.
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Figure 4.3 Fractionation of adenine dinucleotide standards by HPLC. A 50 uL sample of
mixed adenine dinucleotide standards, containing an equal 1 uM concentration of ApsA,
ApsA and Ap¢A, was bound to a MonoQ ion exchange column andeluted at 1 mL/min with a
linear gradient of ammonium bicarbonate, pH9.6, between 21 mM and 0.7 M overa total
volumeof 20 mL.Fractions (0.5 mL) were collected and the amount of adenine dinucleotide
in each was determined using a specific luminometric assay, as described on pg. 47.
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Figure 4.4 Fractionation of cell extracts by HPLC. A nucleotide was extract prepared from
approximately 4 x 10’ wild-type AA8 cells, bound to a MonoQ ion exchange column and
eluted at 1 mL/min with a gradient of ammonium bicarbonate, pH9.6, between 21 mM and
0.7 M.Fractions (0.5 mL) were collected and the amount of adenine dinucleotide in each was
determined using a specific luminometric assay, as described on pg. 46. The arrowsindicate
the elution fraction of the dinucleotide standards.
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4.2.8 The increase in adenyl dinucleotides following DNA damage appears not to
consist of ApsA alone
To further characterise the nature of the increased level of adenyl dinucleotides which
accumulates in cells following DNA damage, an extract from EMSand araC-treated AA8
cells was also fractionated by HPLC and each fraction subsequently assayed for Ap,A. The
treatment conditions were identical to those which were previously found to increase the
overall level of Ap,A (Fig. 3.2, pg. 62), although the additional use of HPLC enabled this
Ap,A to be examined in more detail and its exact composition determined. In comparison to
untreated AA8 cells (Fig. 4.4), the EMS and araC-treated AA8 cells showed striking
difference (Fig. 4.5A). In addition to the peak of material co-eluting with the Ap4A standard,
a second, much larger peak of material was also detected eluting after the Ap4sA. Similarly,
this was also observed in untreated EM9 cells, which were earlier found to have a
constitutively high level of ApsA (Fig. 4.5B). This important finding appears to indicate that
the previously reported increase in Ap4sA following EMS-treatment is actually not ApyA
alone, and in fact a substantial portion ofit is another, as yet unidentified compound whichis
also detected by the assay technique. Although eluting in a similar position, this material
appeared not to co-elute with the ApsA standard, yet it must be sensitive to hydrolysis by
NUDT2inorder to be detected by the assay. Based onthis, the most likely explanationis that
it is in fact a form of ApyA which has been modified in some way which causesit to be
separated from unmodified Ap4A during HPLC.
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Figure 4.5 Fractionation of cell extracts by HPLC. (A) AA8cells were treated for 4 h with
200 mMethyl methanesulphonate (EMS) in combination with 200 mM cytosine arabinoside
(araC) and immediately extracted for analysis. (B) Untreated EM9 cells (XRCC1 deficient).
In each case, nucleotide extracts from approximately 4 x 10’ cells were bound to a MonoQ
ion exchange column and eluted at 1 mL/min with a gradient of ammonium bicarbonate,
pH9.6, between 21 mM and 0.7 M.Fractions (0.5 mL) were collected and the amount of
adenine dinucleotide in each was determined using a specific luminometric assay, as
described on pg. 46. The arrowsindicate the elution fraction of the dinucleotide standards.
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4.2.9 The increased ApsA detected following DNA damage appears to be modified by
ADP-ribosylation
An intriguing possibility for the identity of the unknown molecule is ADP-ribosylated ApyA
(Fig. 1.4), which has been reported to be produced under certain conditions in vitro
(Yoshihara & Tanaka, 1981), however until now has never been detected in vivo. Given that
ADP-ribosylationis primarily carried out by PARP enzymes, which have an importantrole in
DNAsingle strand break repair, this seemed a very interesting hypothesis to investigate.
To examine if this might be the case, a sample of ADP-ribosylated Ap4A wasinitially
synthesised in vitro using purified, recombinant PARP-1 enzyme to produce ADP-ribose
from NAD”substrate and attach it onto Ap4A as an acceptor. This has previously been shown
to occur efficiently under certain conditions, andin the presence of histone H1 (Tanakaet al.,
1981). As shown in Fig. 4.6A, following the synthesis reaction and subsequent fractionation
of the products, a second peak of material elutes after the unmodified ApsA, which
presumably corresponds to mono-ADP-ribosylated Ap4sA, since it was not detected in a
control reaction in the absence of PARP-1 (Fig. 4.6B). This co-eluted with the peak of
unknown material detected in both EM9 cells and EMS-treated AA8 cells, supporting the
theory that it is in fact ADP-ribosylated ApsA. An additional, smaller peak also elutes later
(fraction 20) which probably corresponds to di-ADP-ribosylated Ap4A, modified by the
addition oftwo ADPribose units.
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Figure 4.6 (A) Synthesis of ADP-ribosylated Ap4,A in vitro by PARP-1. A total reaction
volume of 50 uL was used, containing 25 mM Tris-HCl, pH8.0, 1 mM DTT, 100 uM Ap,sA,
25 uM NAD’, 5 ug histone H1, 10 wg PARP active DNA and 20 pg PARP-1 enzyme. (B)
Negative control reaction, as above except without PARP-1. Reactions were incubated at 25
°C for 18 h and then the enzyme was deactivated by incubating for 10 minutes at 95 °C and
centrifuging for 10 mins at 9,000 x g. The supernatant was bound to a MonoQion exchange
column and eluted at 1 mL/min with a gradient of ammonium bicarbonate, pH9.6, between
21 mM and0.7 M.Fractions (0.5 mL) were collected and the amount of adenine dinucleotide
in each was determined using a specific luminometric assay, as described on pg. 46. The
arrowsindicate the elution fraction of the dinucleotide standards.
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To provide further evidence that ADP-ribosylated ApsA had been detected in vivo, EM9cell
extracts were treated with purified recombinant poly(ADP-ribose) glycohydrolase (PARG),
the enzyme which functions to reverse the poly(ADP-ribosylation) reaction by removing
ADP-ribose and restoring the acceptor molecule to its original, unmodified state. Following
treatment of EM9cell extracts with PARG and subsequentfractionation, there was a distinct
change in the elution pattern of the nucleotides (Fig. 4.7B). The second peak thought to
correspond to ADP-ribosylated Ap4sA was no longer present and all of the material now co-
eluted with the Ap4sA standard. Since the unidentified material detected in untreated EM9
extracts (Fig. 4.7A) is clearly sensitive to PARG, and is apparently restored to unmodified
Ap4A following treatment with PARG,this provides fairly strong evidence that it is in fact
ADP-ribosylated ApsA.
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Figure 4.7 Treatment of EM9cell extracts with poly-(ADPribose) glycohydrolase (PARG).
(A) Untreated nucleotide extract prepared from approximately 4 x 10’ EM9 cells (B)
Nucleotide extract prepared as above and then incubated at 37 °C for 18 h in a total reaction
volume of 100 yL containing 25 mM Tris-HCl, pH8.0, 10 mM £-mercaptoethanol and 10 pg
recombinant PARG.Following incubation, the enzyme was deactivated by incubating for 10
minutes at 95°C andcentrifuging for 10 mins at 9,000 x g. The supernatant was boundto a
MonoQ ion exchange column and eluted at 1 mL/min with a gradient of ammonium
bicarbonate, pH9.6, between 21 mM and 0.7 M.Fractions (0.5 mL) were collected and the
amount of adenine dinucleotide in each was determined using a specific luminometric assay,
as described on pg. 46. The arrowsindicate the elution fraction of the dinucleotide standards.
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4.2.10 ADP-ribosylated ApsA might not be synthesised by PARP-1 in vivo
Poly(ADP-ribosylation) of various proteins during SSBRis primarily carried out by PARP-1,
which was also shown above to carry out ADP-ribosylation of ApsA in vitro. To investigate
whether PARP-1 might also be responsible for ADP-ribosylation of Ap4sA in vivo, it was
decided to examine nucleotide extracts from EM9 cells grownin the presence of a PARP-1
inhibitor. NU1025 (Fig. 4.8B) is a structural analogue of NAD* (Fig. 4.8A) and is a potent
PARP-1 inhibitorsinceit has a greater ability to interact with the enzyme compared to NAD*
(Griffin ef al., 1995). The results obtained (Fig. 4.9) initially appear to indicate that PARP-1
inhibition had no effect on the Ap,A detected, suggesting that PARP-1 might not be
responsible for ADP-ribosylation of Ap4A in vivo. However,the lack of a control mechanism
to confirm the success of PARP-1 inhibition prevents any valid conclusions from being made.
Furthermore, the data is very puzzling since the elution fractions appear to have shifted, with
the nucleotides eluting from the column earlier than expected. This inconsistency with
previous experiments could be indicative of a problem with the HPLC process on this
particular run.
Given the ambiguous data and the concerns aboutits validity, it is certainly not possible to
draw any definitive conclusions from this experiment. However, the data has been included
here because it worth considering the interesting possibility that ADP-ribosylation of ApyA
may actually be carried out by another enzyme besides PARP-1. There are 17 human genes
encoding PARP family enzymes, although only two of these appear to have a role in DNA
repair. The second such member besides PARP-1 is PARP-2, whichis also activated in both
the SSBR and BER pathways (Ameef al., 1999). It has a different DNA binding domainto
PARP-1 and seems to be involved in later stages of repair (Mortusewicz ef al., 2007),
althoughit doesalso interact with XRCC1, pol-B and Lig3a (Schreiberet a/., 2002). The high
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potency of the NU1025 inhibitor appears to be specific to PARP-1 withits structure giving it
an improved ability to interact with that enzyme in comparison with the usual NAD*
substrate (Griffin et al., 1995; Ruf et al., 1998). Since NU1025 is a structural analogue of
NAD’,it is likely to inhibit all PARP enzymes to a certain degree, although at the low
concentration used here, this effect is unlikely to be significant for other PARP enzymes
besides PARP-1. Therefore, it could be the case that PARP-2 actually carries out ADP-
ribosylation of ApsA which would provide an explanation of why this appeared not to be
affected by NU1025 treatment. It is also a possibility that ADP-ribosylation of ApsA is
carried out by a different enzyme such as a mono-ADP-ribosylase unrelated to PARP. Dueto
time and equipment constraints, it was not possible to repeat this experiment within the
present study or to investigate further by using a specific PARP-2 inhibitor such as UPF1035
(Moroni ef al., 2005) or a general inhibitor of both PARP-1 and PARP-2. Howeverthis is
certainly something that should be carried out as part of further investigation inthis area.
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Figure 4.8 (A) Chemical structure of NAD” with the nicotinamide moiety (recognised by
PARP-1) highlighted within the box. (B) Chemical structure of the PARP-1 inhibitor
NU1025.
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Figure 4.9 Fractionation of cell extracts by HPLC. (A) Untreated EM9 cells extracts. (B)
EM9cells were treated with NU1025 for 18 h and then extracted for analysis. In each case,
nucleotide extracts from approximately 4 x 10’ cells were bound to a MonoQ ion exchange
column and eluted at 1 mL/min with a gradient of ammonium bicarbonate, pH9.6, between
21 mM and 0.7 M.Fractions (0.5 mL) were collected and the amount of adenine dinucleotide
in each was determined using a specific luminometric assay, as described on pg. 46. The
arrowsindicate the elution fraction of the dinucleotide standards.
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4.3 Discussion
While further work is clearly required to conclusively prove the origin of DNA-damage
related Ap4yA accumulation, the evidence gathered here provides a strong suggestion ofits
source and the mechanism ofits synthesis.
Synthesis of ApsA is already knownto be carried out by ligase family enzymes and Lig3a
has specifically been shown to be one such enzyme (McLennan, 2000). This Ap4A synthesis
is inhibited in vitro by the presence of either ligatable or non-ligatable DNA, suggesting it
specifically occurs only when Lig3a is not bound to DNA.Thefinding here that the level of
intracellular Ap4A is increased in cells treated with L67, appears to indicate that Lig3a also
produces Ap,A in vivo asa result ofits inability to bind to DNA dueto the effect of the
inhibitor. This is supported by the increased level of ApsA also detected in EM9cells, in
which XRCC1-Lig3a complex formation does not occur due to the lack of XRCC1. In these
cells, Lig3a is not targeted to DNA since this is mediated by its interaction with XRCC1
(Caldecott et al., 1995; Cappelli er al., 1997). Taken together, these observations support a
model in which Lig3a produces ApsA in vivo as a consequence ofits inability to bind to
DNA,orits inability to participate in a multiprotein complex required for this to occur, as is
the case in EM9. This is also consistent with the increased Ap4A in wild-type cells following
DNA damage, since Lig3a may be prevented from binding to DNA immediately following
DNA damagedueto the prior transient binding of PARP-1. To further examine the possible
role of Lig3a in producing Ap,gA in vivo, it would be extremely useful to examine DNA
damage-related ApsA accumulation in Lig3a-deficientcells. If this did not occur normally, it
would provide a very strong indication that this function was indeed carried out by Lig3a.
Unfortunately, such cells were unavailable while the work reported here was being carried
out, although a Lig3a knockout mousecell line has recently been produced (K.W. Caldecott,
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personal communication), which is likely to prove a valuable tool for uncovering further
information on therole of Lig3a.
Despite the apparent role of Lig3a in the synthesis of Ap4A,it appears that the level of ApsA
is substantially higher in EM9 cells which lack XRCC1 entirely than in L67 treated cells
(data summarised in Table 4.6). This suggests that there may be another factor responsible for
the increased ApsA in EM9 cells in addition to Lig3a. The important finding that APTX
deficient cells clearly do have a significantly increased level of Ap4sA (Table 4.3) gives a
strong suggestion that this protein also has some involvement in the regulation of ApyA
levels, and the DNA damagerelated increases in ApsA which occur. The catalytic HIT
domain of APTX haspreviously been reported to have a low level of Ap4A hydrolase activity
in vitro (Kijas et al., 2006), and this was confirmed here with a similar, low level of activity
being detected (Table 4.4). This relatively weak ApsA hydrolase activity is arguably too low
to make a significant change to the ApsA level in vivo, and its activity did not appear to be
increased by binding to recombinant phosphorylated XRCC1, as is the case for PNK which
shares a similar XRCC1-binding FHA domain with APTX (Whitehouse ef al., 2001;
Clements et al., 2004). However, since XRCC1-APTX is actually part of a much larger
multiprotein complex in vivo, it could be the case that APTX activity is increased by the
presence andinteraction of other components of the complex, besides XRCC1. Since APTX
interacts with these otherproteins indirectly through XRCC1 (Hiranoef al., 2007), this would
not occur in EM9cells, resulting in reduced hydrolytic activity and increased Ap4A.Also,it
is possible that the stability of APTX is reduced without XRCC1 binding, which maylead to
reduced APTX,also contributing to reduced Ap4A hydrolysis and higher Ap4A.
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Table 4.6 Summary table showing the level of Ap4sA present in various cell lines and
conditions.
 Cell line and treatment Ap4A (pmol/10° cells) Fold difference to
untreated AA8
AA8 0.63 + 0.07 (n=6) -
AA8 + L67(ligase inhibitor) 2.72 (n=2) 4.3
EM9 9.96 + 1.65 (n=6) 15.8
H9T3-7-1 (EM9 + XRCC1) 0.78 + 0.06 (n=4) 1.24
Taken together, the data reported here are consistent with a model in which the very high
level of ApsA in EM9is caused by a combination of both increased synthesis (by Lig3a), and
decreased degradation (by APTX). Where either only Lig3a or only APTX is affected, an
increase in ApsA does occur, but it is lower than that occurring in the absence of XRCC1,
whichislikely to affect both proteins.
The apparent synthesis of ADP-ribosylated ApsA in response to DNA damage provides a
very interesting clue asto the potential role of increased Ap4A in the DNA damageresponse.
ADP-ribosylation of proteins is an important feature of SSBR andis primarily carried out by
PARP-1 (de Murcia ef al., 1994). Despite the earlier identification of ADP-ribosylated ApsA
in vitro (Yoshihara & Tanaka, 1981), its occurrence has never been reported before in vivo.
Its synthesis in cells in response to DNA damageisparticularly intriguing since it has been
previously foundto be an effective inhibitor of SV40 DNAreplication in vitro. Therefore,it
could form a novel part of the cellular mechanism to inhibit and stall DNA replication in
response to DNA damagewhile repair occurs.
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CHAPTER 5
Ap,4Aincreasestheability of cells to survive after exposure to
EMS
5.1 Introduction
The experiments carried out in the previous chapters have added to the existing evidence
which suggests that ApsA has a role in the DNA damage response, and have provided some
important information about a possible source of the DNA damagerelated increase in Ap4A.
However, until now, there has been no clear evidence that the excess Ap4A synthesised in
response to DNA damage actually has any function and what the nature, importance or
relevance of this function may be.
To investigate the possible functional significance of Ap4A in the DNA damageresponse,it
would be extremely useful to havecell lines available in which the level of intracellular ApyA
could be increased or decreased independently of DNA damage, in order to examine what
effect this has on the cells’ ability to respond normally to DNA damage. By using various
techniques to measure DNA damage and repair, such cells could provide valuable
information aboutthe possible role of Ap4A in these importantcellular processes.
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5.2 Results
5.2.1 Production of ApsA-deficient AA8cells
To gather some information about the possible functional significance of Ap4A in the DNA
damage response,it was decided tofirst examine the effects that the absence of Ap4A has on
this response. In order to do this, a stably transfected cell line was established in which the
human NUDT2 enzymecan be over-expressed in order to continually hydrolyse intracellular
Ap4A,thus eliminating it from the cell.
To achieve this, the ‘Rheoswitch’ mammalian expression system (New England Biolabs) was
used. This system uses two individual plasmids, both a regulatory plasmid (pNEBR-R1) and
a separate vector plasmid (pNEBR-X1Hygro) in which the expression sequence is cloned.
The pNEBR-R1plasmid (Fig. 5.1) constitutively expresses two regulatory molecules (termed
RheoReceptor-1 and RheoActivator) that interact to form a heterodimer which bindstightly
to a region of the pNEBR-X1Hygro vector plasmid (Fig. 5.2A), just upstream of the cloned
gene. The heterodimer is normally in a transcriptionally inactive form and this binding to
pNEBR-X1Hygrotightly represses expression of the cloned gene. However, addition ofthe
RSL1 inducer ligand (Fig. 5.3), which binds to the RheoReceptor-1 protein, induces a
conformational change in the RheoActivator that stabilises and activates the heterodimer.
This results in recruitment ofthe basal transcription machinery and a high level of expression
of the cloned gene. The benefits of this system are a very low backgroundlevel of expression,
and the fact that gene expression can be induced and tightly controlled by varying the
concentration of RSL1 in thecells’ growth medium.
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(B-lactamase)
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RheoActivator
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Figure 5.1 Plasmid map of the ‘Rheoswitch’ regulatory plasmid pNEBR-R1. This plasmid
expresses two regulatory proteins termed RheoReceptor-1 and RheoActivator from the
constitutive UbC and UbB promoters respectively. Together, these molecules form a
heterodimer which regulates the transcription of genes cloned into the pNEBR-X1Hygro
vector. The plasmid also contains the G418 resistance gene under the control of the SV40
early promoter to allow selection of cells carrying the plasmid and the generation of stably
transfected cell lines. The diagram is based on the sequence information provided by the
manufacturer.
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.-ACTACCAGAGCTCATGGG CCCGTGCAATTGAAGCCGGCTGGCG CCAAG CTTCTCTGCAGGATAT
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BsrGi Sphi Sall Stul
GCGTCTCCGGATGTACAGGCATGCGTCGACCCTCTAGTCAAGGCCTATAGTGAGTCGTATTACG....
Figure 5.2 (A) Plasmid map of the ‘Rheoswitch’ expression vector plasmid pNEBR-
X1Hygro. The gene for expression is cloned into the multiple cloning site (MCS), ahead of a
TATAboxand short leader sequence, and followed by an SV40 polyA signal. There are five
copies of the GAL4 response element (SXRE) also upstream of the MCS which function as a
binding site for the RheoReceptor-1/RheoActivator heterodimer that regulates transcription
of the cloned gene. The plasmid also contains the hygromycin resistance gene to allow
selection of cells carrying the plasmid and the generation of stably transfected cell lines. (B)
Multiple cloning site (MCS) of the pNEBR-X1Hygro vector plasmid. The BamHI and Xhol
restriction enzymesites were used to clone the NUDT2 cDNAinto the vector. The diagrams
are based on the sequence information provided by the manufacturer.
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Figure 5.3 Chemical structure of the ‘Rheoswitch’ inducerligand RSL1.
Initially, the wild-type CHOcell line AA8 wasstably transfected with the regulatory plasmid
pNEBR-R1, and successfully transfected cells were selected by resistance to G418, whichis
conferred by the plasmid. The appropriate concentration of G418 to use for selection was
determined experimentally by first constructing a G418 survival curve (Fig. 5.4). Based on
the findings, a concentration of 500 ug/mL was chosenforselection, since this wassufficient
to result in 100% lethality of untransfected cells. The transfection efficiency was calculated to
be 22.0% from the proportion of cells able to form colonies in the presence of G418,
compared to that in the absence of G418. Following selection, a G418 survival curve was
also constructed for the transfected cells to measure the increase in G418 resistance relative
to untransfected cells (Fig 5.4). Comparison of the two D37 values (Table 5.1) indicates a
four-fold increase in resistance, confirming the presence of the pNEBR-R1 plasmid and the
successof transfection.
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Table 5.1 Resistance to G418 of wild-type AA8 cells and AA8 transfected with the pNEBR-
R1 plasmid. Resistance is presented as D37 values (concentration of G418 required to produce
37% survival) and fold resistanceis in relation to the wild type cell line AA8.
 
 
 
 
Cell line D37 value (ug/mL G418) Fold resistance
AA8 WT 232 -
AA8 pNEBR-RI1 946 4.0
100.0
_ 10.0 —~H=
8z
]Nn
1.0
O C+ L 1 J
0 500 1000 1500 2000
Dose of G418 (ug/mL)
Figure 5.4 Survival response ofcells to increasing doses of G418. Wild-type AA8cells (blue
circles) are sensitive to G418, with 100% lethality occurring at 500 ug/mL.Cells transfected
with the pNEBR-R1 plasmid (red squares) are resistant to G418 due to the presence of the
resistance gene on the plasmid. In both cases at least 200 cells were plated out into dishes,
G418 was added to the medium and dishes were incubated for 10 days, after which the
surviving colonies were counted. At least three replicates were used for each dose and each
data point represents the mean of 2 independent experiments.
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Following transfection and selection, cells were plated out to form a series of individual
single cell derived clones, which were each examined for the level of gene expression, both
before and after RSL1 induction, using a luciferase based reporter assay. Twelve clones were
each transiently transfected with the pNEBR-X1GLuc reporter plasmid (Fig. 5.5), which is
derived from the pNEBR-X1Hygro vector plasmid, and encodes an excreted luciferase
enzyme isolated from the marine copepod Gaussia princeps. The enzyme catalyses the
hydrolysis of the substrate coelenterazine which produces light. Following transfection of
cells with pNEBR-X1GLuc, maximum luciferase expression was induced in each clone by
addition of RSL1. A sample of culture medium wastaken both immediately before, and 18 h
after RSL1 addition and the level of luciferase activity was assayed as a measure ofthe level
of induced gene expression by RSL1 (Table 5.2). Based on this data, clone 8 was chosen for
transfection with the NUDT2 expression vector, based on the low level of background gene
expression, and more importantly, the extremely high level of expression when induced by
RSLI.
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4,821 bp    Ampicillinresistance gene(B-lactamase)pUC19 origin of replication
Figure 5.5 Plasmid map of the ‘Rheoswitch’ control plasmid pNEBR-X1GLuc. This plasmid
is derived from pNEBR-X1Hygro and contains the Gaussia princeps luciferase reporter
cDNA sequence underthe control of the RheoReceptor-1/RheoActivator heterodimer which
bindsto the five copies of the GAL4 response element (5SXRE) just upstream of the sequence.
Upon induction by the RSL1 ligand, luciferase is expressed and secreted, allowing an
accurate measure of gene expression by the assay of luciferase activity in the cells growth
medium. The diagram is based on the sequence information provided by the manufacturer.
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Table 5.2 Comparison of luciferase reporter gene expression in clones of AA8 cells
transfected with the ‘Rheoswitch’ pNEBR-R1 regulatory plasmid. Each clone wastransiently
transfected with the pNEBR-X1GLuc plasmid, which encodesa secreted luciferase under the
control of the pNEBR-R1 plasmid. Therelative level of luciferase activity in the cells growth
medium was measured in the medium by luminometric assay both before and after induction
of gene expression by the addition of 500 nM RSL1. Clone 8 (bold) showsthe highestlevel
of gene induction following RSL1 addition and the highest induction ratio.
 Clone Relative gene expression Relative gene expression Induction
number before RSL1 addition after RSL1 addition ratio
1 24 2009 83.7
2 17 780 45.9
3 28 3778 134.9
4 5 1110 222.0
5 13 4270 305.0
6 25 1456 58.24
7 27 892 33.0
8 6 4834 805.7
9 12 2137 178.1
10 57 3344 58.7
i 24 357 14.8
12 30 4552 151.7
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The human NUD72 cDNAsequencewassupplied as a bacterial clone carrying a recombinant
pOTB7plasmid with the NUDT2 cDNAsequencecloned into the plasmid between the EcoRI
and XhoI restriction enzymesites (Fig. 5.6). Following miniprep extraction, a restriction
digest and subsequent agarose gel electrophoresis were carried out on the plasmid DNA to
confirm that the correct clone had been received (Fig. 5.7). The NUDT2 cDNA sequence was
then amplified from the recombinant plasmid by PCR. The primers used (Table 5.3) were
designed to incorporate appropriate restriction enzyme sites on to the ends of the PCR
productto facilitate its cloning into the multiple cloning site (MCS) of the pNEBR-X1Hygro
expression vector (Fig. 5.2B). Following PCR, amplification of the correct 464 bp product
wasconfirmed by agarosegel electrophoresis (Fig. 5.8).
EcoR1
 
  
 
Chloramphenicol
resistance gene
(CAT)
pOTB7 + human
    Cloned human
 
    NUDT2 cDNA NUDT2 cDNA2,706 bp (911 bpinsert)(1,795 bp plasmid + 911 bp
insert)
 
   /
Origin of
replication Xhol
Figure 5.6 Plasmid map of the pOTB7vector as received from the I.M.A.G.E. consortium
(ID: 3623134), with the human NUDT2 cDNA sequence cloned between the EcoR1 and
Xho1 restriction enzyme recognition sites. The diagram was constructed using the
information provided by the supplier.
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Table 5.3 PCR primers used for the amplification of NUDT2 cDNA sequence from
recombinant plasmid DNA.Primers were designed to incorporate appropriate restrictionsites
(lowercase) into the PCR product in order to facilitate cloning into the pNEBR-X1Hygro
expression vector.
 Primer Sequence Melting temperature
(Tm)
BamHI
F primer 5'-TggatecGACCATGGCCTTGAGAGC-3’ 39 °C
Xhol
Rprimer 5'-TctegagGCTCAGGCCTCTATGGAG-3' 59 °C
‘ pOTB7 plasmid
(1,795 bp}
¢— Human NUDT? cDNA
(911 bp)
 
Figure 5.7 Restriction digest of recombinant pOTB7 plasmid containing human NUDT2
cDNA following agarose gel electrophoresis. Lane 1 contains the DNA size markers. Lanes 2
and 3 contain undigested plasmid, while lane 4 contains plasmid following digestion by
EcoR1 and Xhol. The 1,795 bp fragment corresponds to the pOTB7 plasmid itself, while the
911 bp fragment correspondsto the inserted cDNA sequence.
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Figure 5.8 Amplification of human NUDT2 cDNA sequence by PCRandvisualisation of
products following agarose gel electrophoresis. Lane 1 is the DNA size markers, while lane 2
is a negative control (no DNA template). The presence of a band in lanes 3 and 4 at
approximately 464 bp indicates product amplification.
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The PCR product was purified and both the PCR product and pNEBR-X1Hygro expression
vector plasmid were digested by BamHI and YXhol restriction enzymes to produce
complementary cohesive ends. The insert was then ligated into the vector and the reaction
product mixture wasused to transform competent E. coli cells. Those cells transformed with
the correct product (vector+insert) were identified by blue-white screening of colonies, before
further amplification and subsequent miniprep extraction of the vector. The insert was then
fully sequenced using appropriate primers to ensure that no mutations had been introduced
and that the sequence wasin the correct reading frame (data not shown).
Finally, the previously selected AA8 pNEBR-R1 clone (Table 5.2) was stably transfected
with the pNEBR-X1Hygro expression vector containing the cloned human NUDT2 cDNA
sequence. This plasmid contains a hygromycin resistance gene, which allowsthe selection of
successfully transfected cells. As described earlier for G418, the appropriate concentration of
hygromycin to use for selection was determined experimentally to be 500 g/mL byfirst
constructing a hygromycin survival curve (Fig. 5.9). The transfection efficiency in this case
was calculated to be 30.2%. Following selection, a hygromycin survival curve was also
constructed for transfected cells and comparison of the two D37 values indicates a 4.5-fold
increase in hygromycin resistance (Table 5.4). This cell line was plated out to form a series of
single cell derived clones and all further experiments were carried out on the samesingle
clone.
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Table 5.4 Resistance to hygromycin of wild-type AA8 cells and AA8 transfected with the
pNEBR-X1Hygro plasmid. Resistance is presented as D37 values (concentration of
hygromycin required to produce 37% survival) and fold resistance is in relation to the wild
type cell line AA8.
 
 
Cell line D37 value Fold resistance
(ug/mL hygromycin)
AA8 WT 218 -
AA8 pNEBR-X1Hygro 982 4.5
100.0
10.0g
sgza
1.0
0 @ l J j 
0 500 1000 1500 2000
Dose of hygromycin (ug/mL)
Figure 5.9 Survival response of cells to increasing doses of hygromycin. Wild-type AA8
cells (blue circles) are sensitive to hygromycin, with 100% lethality occurring at 500 ug/mL.
Cells transfected with the pNEBR-XlHygro plasmid (red squares) are resistant to
hygromycin due to the presence of the resistance gene on the plasmid. In both cases,at least
200 cells were plated out in dishes, hygromycin was added to the medium and dishes were
incubated for 10 days, after which the surviving colonies were counted. At least two
replicates were used for each dose.
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5.2.2. Characterisation of ApsA-deficientcells
In order to confirm that the transfected NUDT2 cDNA wasexpressed and underthe control
of RSL1, an immunoblotusing an anti-NUDT2 antibody wascarried out on extracts from the
transfected cell line grown in increasing concentrations of RSL1 (Fig. 5.10). The visual
intensity of the target protein band increased considerably with increasing concentration of
RSLI, indicating an increase in the level of NUDT2 expression. To further confirmthat the
increased NUDT2 wascatalytically active, and to provide a quantitative measurement ofthis
activity, an ApyA hydrolase enzymeactivity assay wasalso carried out on thecell lysates. At
the maximumlevel of expression (500 nM RSL1), a 42-fold increase in ApsA hydrolytic
activity was detected in the transfected cell lysates over wildtype cells (Fig. 5.11).
 
i 2 3
NUDI2-=> —
RSL1 conc. >» 0 5 50 100 500 Purified
{nm} recombinant
protein
Figure 5.10 Expression of human NUDT2 as detected by immunoblotting. Whole cell
extracts were prepared from AA8 cells transfected with pNEBR-R1/pNEBR-
X1HygrotNUDT2andcellular proteins were immunoblotted with an anti-NUDT2antibody.
Un-induced cells express a relatively low level of NUDT2 (lane 1) which increasesas cells
are grown in increasing concentrations of the inducer ligand RSL1 (lanes 2-5). Purified
recombinant NUDT2 wasalso detected as a positive control (lane 6). B-actin was detected in
all cell extracts as a loading control (data not shown).
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Figure 5.11 Measurement of relative ApsA hydrolase enzyme activity in extracts from
pNEBR-R1/pNEBR-X1Hygro+NUD72transfected cells grown in increasing concentrations
of the inducer ligand RSL1. Whole cell extracts were prepared using a non-denaturing protein
extraction buffer and enzymeactivity was determined by addition of a portion of the extract
to an excess of ApsA substrate. The activity was measuredbythe rate of formation ofATP (a
product of the reaction) as detected by a luminometric assay (pg. 56). All values show the
activity relative to that detected in wild-type AA8cell extracts.
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To determine the extent to which this level ofNUDT2 over-expression is capable of reducing
or eliminating intracellular Ap4A, the basal level of ApsA was measured in both the wild-type
cell line and the fully induced transfected cell line. Even at the maximum level of NUDT2
expression, a low background level of ApsA was foundto persist in transfected cells (Table
5.5), although this is possibly due to a compartmentalised pool of Ap4A, inaccessible to the
enzyme and unlikely to be related to the possible role of Ap4sA in the nucleus. Indeed,
synthesis of ApyA by mitochondrial enzymes has previously been reported (Krauspe ef al.,
1988), and given its widespread presence,it is likely that a pool of ApsA exists within these
organelles.
In order for the transfected cell line to be useful in establishing a role for ApyA in DNA
repair, it must be able to resist the increase in Ap4A that usually occurs in response to DNA
damage. Therefore, it was important to examine the ability of the transfected cell line to
maintain a low level of ApsA under conditions which normally cause it to increase. As found
previously (Table 3.2, pg. 66), in wild-type AA8cells, the level of Ap4A is increased 2.1-fold
following a 4 hour treatment with ethyl methanesulphonate (EMS). Upon examination ofthe
level of ApsA in the transfected cell line following the same EMStreatment, there was no
increase (Table 5.5), indicating that the over-expression of ApsA hydrolase wassufficient to
prevent this from occurring. Toassess the ability of the transfected cell line to resist a much
larger increase in the level of Ap4A, both cell lines were treated with a combination of EMS
and araC, which waspreviously found to significantly increase the level of ApsA in wild-type
cells up to 13-fold higher than the basallevel. In the transfected cell line, a small increase in
Ap4A wasobserved, although the maximum level remained low and was comparableto the
basal level of wild-type cells (Table 5.5, Fig. 5.12).
Table 5.5 Ap,A levels in wild-type AA8 cells and in transfected AA8 cells over-expressing
human NUDT2. Both cell lines were treated for 4 hours with 200 mM ethyl
methanesulphonate (EMS) in the presence and absence of 200 uM cytosine arabinoside
(araC), and then intracellular ApsA was immediately extracted and assayed. Each valueis the
mean + S.E.M. of independenttriplicate determinations. P values were calculated using a
paired t-test and representthestatistical significance of the observed difference between the
level of Ap4Ain cells after the treatment indicated and that in untreatedcells.
 Cell line Treatment ApsA (pmol/10° cells) Fold difference to P value
untreated cells
AA8 None 0.69 + 0.07 - -
EMS 1.42 + 0.22 2.1 0.036
EMS+ araC 9.23 + 1.24 13.4 0.0023
AA8 None 0.22 + 0.04 - -
(transfected) EMS 0.21 + 0.07 0.95 0.97
EMS+ araC 0.84 + 0.19 3.8 0.03
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Figure 5.12 Increase in Ap4A levels of wild-type AA8 cells (blue circles) and transfected
AA8cells over-expressing human NUDT2 cDNA(red squares) in response to treatment with
increasing doses of EMS in combination with 200 uM araC. Cells were treated for 4 h and
then intracellular Ap4A was immediately extracted and assayed. The data represents the mean
of three independent determinations and the error bars represent the standard error of the
mean (S.E.M.). Someerror bars are smaller than the marker size and are therefore not visible
in the figure.
Based on the information gathered about the newly engineered cell line, it appears that the
intracellular level ofNUDT2activity can be increased by up to 40 times the normal level and
this results in both a low background level of Ap4A, and a substantial reduction in the usual
DNA damage-induced increase. Therefore, this cell line has the potential to be an extremely
useful tool to examine what effects the lack of ApsA has on various aspects of the DNA
damageresponse, and therefore to provide aninsight into a possible role for Ap4A in this.
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5.2.3 Ap4A-deficient cells are more sensitive to EMS than wild-typecells
Following the successful establishment of a cell line deficient in ApsA through the over-
expression of NUDT2,it was decidedto use these cells for some preliminary investigations as
to what effects this may have on the DNA damageresponse. Previous evidence suggests a
possible role for ApsA in the SSBR and BER pathways, and the level of ApyA normally
increases following treatment with agents which induce the type of damage repaired by these
pathways, such as EMS and MMS.Inaddition, the level of Ap4A is substantially elevated in
XRCC1-deficient cells, which are defective in the SSBR and BER processes. To determine if
this DNA damage-related increase in ApsA may havea function inthe cell, it was decided to
firstly examinethe ability of ApsA-deficientcells to survive following treatment with EMS.
Both wild-type AA8 cells and the transfected cells deficient in ApsA through NUDT2 over-
expression were treated with increasing concentrations of EMS and the proportion of
surviving cells was measured by their ability to form colonies. The data showed a clear
difference between the twocell lines (Fig. 5.13), with the ApsA deficient cell line showing a
much higher sensitivity to EMS than the wild-type cell line. Comparison of the two D37
values (Table 5.6) indicates that the cells lacking ApsA have a 3.4-fold higher sensitivity to
EMSthan those with a normal level of Ap4sA. This very interesting finding provides the
strongest suggestion yet that ApsA may be functionally involved in the DNA damage
response and/or DNArepair processes. Clearly, further work is required to confirm these
findings and to substantiate them by examining the response of Ap4A-deficient cells to
various other DNA damaging agents and by probing the exact mechanism by which the lack
of Ap4A contributes to the increased sensitivity of the cells to EMS.
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Table 5.6 Sensitivity to EMS of wild-type AA8cells and transfected AA8cells deficient in
Ap4A due to the over-expression of human NUDT2 cDNA.Sensitivity is presented as D37
values (concentration of EMS required to produce 37% survival) and fold sensitivity is in
relation to the wild type cell line AA8.
 
 
Cell line D37 value (mM EMS) Fold sensitivity
AA8 18.0 -
AA8transfected 5.27 3.4
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Figure 5.13 Survival responses of wild-type AA8cells (blue circles) and transfected cells
deficient in Ap,A due to the over-expression human NUDT2 cDNA (red squares) after
treatment with increasing doses of EMS.At least 200 cells were plated out in each dish and
allowed to attach for 4 h, after which the medium was removed and attached cells were
washed once with HBSS.Cells were then treated with EMS for 1 h in 10 mL serum free
medium, which was then removed and replaced with normal medium. Dishes were incubated
for 10 days, after which the colonies were counted and used to calculate the proportion of
surviving cells compared to untreated controls. At least three replicates were used for each
dose and each data point represents the means of 3 independent experiments. The error bars
represent the standard error of the mean (S.E.M.). Some error bars are smaller than the
markersize and are therefore not visible in the figure.
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5.2.4 Production of ApsA-deficient XRCC/ mutant EM9cells
It was previously found that cells lacking the DNA repair protein XRCC1 have a
substantially increased level of intracellular ApsA in comparison to wild-type cells. These
cells have a numberofdistinctive phenotypic characteristics, including a hypersensitivity to
DNAalkylating agents, a reduced ability to repair DNA strand breaks and a high background
level of sister chromatid exchanges (Thompsonef a/., 1982). An interesting possibility is that
someof the cellular phenotypes of XRCC1-deficient cells might actually be partially caused
by the increased level of Ap4sA, rather than directly caused by the lack of XRCC1. To
investigate this, it was decided to also produce a strain of the XRCC1-deficient cell line EM9
in which over-expression of NUDT2 can be induced and controlled, in order to eliminate
intracellular Ap4A,or to reduceit back to the level occurring in wild-type cells.
As described above for AA8, EM9cells were transfected with the pNEBR-R1 regulatory
plasmid and successfully transfected cells were selected by resistance to G418. The
transfection efficiency was 27.3%, and following transfection, cells were subsequently plated
out to form a series of single cell-derived clones. These were then examined for the level of
luciferase reporter gene expression both before and after the addition of RSL1. Based on this
data, one clone was chosen for transfection with the pNEBR-X1Hygro expression vector
plasmid containing the NUDT2 cDNAsequence. Following transfection, cells were selected
by their resistance to hygromycin and plated out to form single cell derived clones.
Unfortunately, examination of the basal level of ApsA in these cells found that it remained
high in each case, even at the maximuminduction of NUDT2 expression by RSL1. Since the
maximum level of NUDT2 over-expressionis insufficient to reduce ApsAto levels to levels
comparable with wild-type cells, it appears that these cells are not useful for the further
experimental work that was planned.
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5.2.5 Increasing intracellular ApsA by expression offirefly luciferase in vivo
In addition to investigating the possible effects that a lack of ApsA might have on the DNA
damageresponse, it would also be useful to investigate the reverse situation and examine the
possible effects caused by an increase in the level of intracellular Ap4A. To achieve this, it
was decided to use a system based on the expression of firefly luciferase, which has
previously been reported to synthesise ApsA in vitro in the presence of its D-luciferin
substrate (Guranowski et al., 1990). The mechanism involves D-luciferin acting as an
adenylate acceptor from ATP, forming luciferyl-AMP which is then converted to
dehydroluciferyl-AMP. The AMP moiety is subsequently transferred to another molecule of
ATP, thus producing Ap4A (Fontes ef al., 1998). More recently, it has been reported that
firefly luciferase also produces ApsA in vivo, subject to the presence of the substrate D-
luciferin in the cells’ growth medium. Over-expression of luciferase produces a very high
level of intracellular ApsA in COS-7 cells, and this can be controlled by altering the level of
D-luciferin in the cells growth medium (Murphy & McLennan, 2004). Over-expression of
luciferase is generally considered non-toxic, and it is widely used as a reporter gene, partly
due to the lack of significant biochemical and physical side effects on transfected cells. It was
therefore decided to exploit this system by over-expressing firefly luciferase in AA8cells, in
order to increase ApsA and provide a direct comparison between the other AA8-derivedcell
lines available.
The wild-type CHOcell line AA8 wastransiently transfected with the pGL3luc plasmid (Fig.
5.14), which encodes the firefly luciferase enzyme under the control of an SV40 promoter
and enhancer sequences whichresults in a constitutively high level of luciferase expression.
D-luciferin was added to the cells’ growth medium 24 h after transfection and cells were
extracted and analysed for ApsA after a further 24 h. The level of ApsA was found to be
128
increased substantially in cells transfected with pGL3luc and grown in the presence of D-
luciferin compared to untransfected cells (Table 5.7). Althoughit is not possible to produce a
cell line stably transfected with pGL3luc due to the lack of a eukaryotic selectable marker,
this is still likely to be a useful tool to examine the possible effects of excess Ap4A on the
DNA damageresponseresponse since it can be transiently applied to any cell line. If ADP-
ribosylated Ap,A is found to be the functional form of Ap4A in vivo, another possible
application for this technique could be as a negative control in order to increase unmodified
Ap4A to confirm that it did not carry out the same function. Unfortunately pGL3luc
transfection was not used further in the present study although the procedure established here
has many potential applications in future work.
SV40 promoter  
 
  
Origin of replication
Firefly luciferase 
  
Ampicillin pG L3luc gene
resistance gene —
(B-lactamase) 5,256 bp
SV40 polyAsignal
S$V40 enhancer
Figure 5.14 pGL3luc plasmid map. This plasmid expressesthe firefly luciferase gene under
the control of the constitutive SV40 promotor and enhancer sequences. The diagram is based
on the plasmid map and sequence information provided by the manufacturer.
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Table 5.7 Ap,A levels in wild-type AA8cells and in AA8cells transfected with the pGL3luc
plasmid which constitutively expresses firefly luciferase. Cells were transfected with
pGL3luc and after 24 h, D-luciferin was added to the medium to a final concentration of 0.5
mM.Cell monolayers were extracted for analysis after a further 24 h and the level of ApyA
was determined using a specific luminometric assay. Each value is the mean + S.E.M. with
the numberof independent determinations (”) in barckets.
 Cell line ApsA (pmol/ 10° cells) Fold difference
AA8 0.71 + 0.14 (n=3) -
AA8 pGL3luc 22.1 + 12.3 (n=4) 31.1
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5.3. Discussion
The work carried out here has produced and characterised a number ofcell lines and
expression systemsthat are likely to be valuable tools for further investigation into the role of
Ap,A in the DNA damageresponse. The establishmentof a stably transfected cell line which
can be induced to significantly over-express the NUDT2 Ap4A hydrolase enzyme has
produced the first cells in which the level of ApsA can be reduced in vivo, and whichresist
the normal increases in ApyA following DNA damage. This provides a new opportunity to
directly examine the phenotype of ApsA-deficient cells, in particular how this affects their
ability to respond normally to DNA damage. The fact that the Ap4A deficientcell line has
been derived from the wild-type CHO strain AA8 allows a direct comparison not only with
wild-type cells, but also other AA8-derived mutants including the YRCCJ/-deficient strain
EM9,whichis also proving to be very important in investigating the possible role of Ap4A.
The establishment of an in vivo over-expression system for firefly luciferase in the samecell
line further enhances the tools available for further work and allows investigation into the
effects of increased ApyA produced through a generally non-toxic and otherwise non-
interfering system. Unfortunately, due to time constraints, the information gathered so far
with these cell lines has been limited, however some interesting observations have been
made.
The finding that cells deficient in ApsA due to the over-expression of NUDT2 have an
increased sensitivity to the alkylating agent EMS is possibly the most important piece of
information reported so far regarding the possible role of Ap4sA in the DNA damageresponse.
Although the possibility exists that the increased EMSsensitivity is caused by some other
unintended effect of NUDT2 over-expression, this seems unlikely given the specificity of the
enzyme for dinucleotides such as ApsA. The level of EMSsensitivity found here for wild-
131
type AA8cells is comparable to the level of sensitivity previously reported for the samecell
line (Thompsonet al., 1982). The 3.4-fold increased EMSsensitivity of Ap4A-deficient cells
indicates that a lack of Ap4A has a significant negative impact on the ability of the cells to
survive the induced DNA damageandtherefore provides a strong suggestion of a functional
involvementin the DNA damage response. However,it is important to note that the increased
EMSsensitivity of Ap4sA-deficient cells is much lower than that of XRCC1-deficientcells
such as EM9 (21-fold increased sensitivity), as would be expected given the core importance
of XRCC1to the BER and SSBRprocesses.
Following on from the findings reportedhere, the cellular tools produced provide an excellent
opportunity to further probe the exact details of Ap4sA involvement in the DNA damage
response. The additional evidence supporting a role for Ap4A in this response makesit more
importantthat the exact nature and mechanism of this be determined.
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CHAPTER6
Discussion
The aim of this project was to investigate the possible role of Ap4A in the DNA damage
response. Although various pieces of existing evidence had suggested that ApyA might have
an involvementin signalling the inhibition of DNA replication in response to damage, this
had never been investigated in detail until now. This project was intended to examine what
function ApyA might have in the DNA damage response and to probe the exact molecular
details of that function.
The increase in Ap4A detected in response to EMStreatment is comparable to those increases
previously reported in various othercell lines following treatment with similar agents, and
supports the existing theory that ApsA is increased specifically in response to DNA strand
breaks (Baker & Ames, 1988). This is further supported by the much larger accumulation of
ApsA when araC wasalso present, which is knownto result in an accumulation of DNA
strand breaks (Hiss & Preston, 1977; Dunn & Regan, 1979). The data here are also consistent
with the observations made by Gilson ef al., 1988, who showed that Ap4sA accumulation was
more pronounced whencells were incubated with the PARP-1 inhibitor 3-AB and that ApsA
persisted throughoutthe incubation period. Since the inhibition of PARP-1 would preventthe
repair of SSBs, it would be expected that breaks would accumulate, therefore accounting for
the ApsA levels observed.
The increased ApsA detected where Lig3a was prevented from binding to its normal DNA
substrate in vivo by the ligase inhibitor L67 is also consistent with previous findingsthat
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Lig3a synthesises Ap4A in vitro andthatthis is specifically inhibited by the presence of DNA
(McLennan, 2000). Therefore, this supports the original hypothesis that Lig3a produces
Ap4A in vivo as a result of its inability to bind its normal DNA substrate. This is likely to
occur in the early stages of SSB repair since Lig3a would be prevented from binding the
break immediately due to the transient binding of PARP-1 (Caldecott ef al., 1996). Although
the primary function of Lig3a in ligating DNA single strand breaks is already well
characterised, it is certainly not an unrealistic scenario that it may also synthesise Ap4yA as a
secondary function undercertain conditions. Indeed, this has already been reported to be the
case for LysRS, which primarily functions as an aminoacyl-tRNA synthetase, but also
appears to also have a secondary function to produce ApsA in immune system mastcells in
response to FceRI-mediated aggregation of these cells (Yannay-Cohen ef al., 2009). To
confirm that DNA damage-induced Ap4A synthesis is primarily carried out by Lig3a, it
would be important to examine DNA damage-related Ap4sA accumulation in Lig3a deficient
cells. If this did not occur normally, it would provide a very strong indication that this
function was indeed carried out by Lig3a. Unfortunately such cells were unavailable during
the present study, but have very recently been produced (K. W. Caldecott, personal
communication).
Another key observation made in the present study is the apparent detection of ADP-
ribosylated ApsA accumulating in cells following DNA damage. ADP-ribosylation of
proteins is already knownto be an important feature of SSBR andis primarily carried out by
PARP-1 (de Murcia et al., 1994). Although the synthesis of ADP-ribosylated ApsA has
previously been reported in vitro (Yoshihara & Tanaka, 1981), until now there has been no
evidence that it also occurs in vivo. The modified ApsA detected here by HPLC ofcell
extracts was found to co-elute with ADP-ribosylated Ap4A synthesised in vitro, and treatment
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of extracts with PARG appeared to convert this back to unmodified Ap4A. Taken together,
these observations provide a fairly strong indication that a substantial proportion of the
increased Ap4sA produced in response to DNA damage is modified by ADP-ribosylation.
Since ADP-ribosylated ApsA is an effective inhibitor of SV40 DNA replication in vitro
(Baker ef al., 1987), this is consistent with its proposed function to stall DNA replication in
vivo. It is also relevant that PARP-1 appears to be required for replication fork slowing in
wild-type DT40 chickencells in response to DNA damage (Sugimuraefa/., 2008). Assuming
that ADP-ribosylated Ap4A contributes to replication fork slowing, this is what would be
expected since the lack of PARP-1 would likely prevent Ap4sA from becoming ADP-
ribosylated and therefore from carrying out its function. In order to confirm the identity of the
modified Ap4yA, mass spectrometry should be carried out on at least partially purified cell
extracts enriched for this material, which will provide definitive information thatit is indeed
ADP-ribosylated. In addition, it would also be very useful to examine whether or not this
material accumulates in PARP-1 knockout cell lines or after the siRNA knockdown of
various PARP family enzymes and/or mono-ADPribosylases. These studies could provide
further evidence supporting its identity as ADP-ribosylated ApsA and the mechanismofits
synthesis.
Taking into accountthe findings madein the present study, an updated model for the possible
role of ApsA in the DNA damageresponse is presented in Fig. 6.1. Overall, the original
hypothesis remains valid, although there may be other factors involved that were not
previously considered. For example, despite the low level of ApsA hydrolase activity that
APTX appears to have in vitro, the fact that a substantially elevated level of Ap4sA was
detected in APTX-deficient cells suggests it may also play some part in the regulation of
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Ap4A levels. On the other hand, this could simply be an indirect effect caused by
accumulation of SSBsin these cells due to defective SSBR in the absence of APTX.
A further key finding fromthe present study is that the basal level of Ap4A is increased by up
to 16-fold in XRCC1-deficient cells. This is consistent with the theory that Lig3a produces
Ap,A where it is unable to bind to DNA, since XRCC1 is required to target Lig3a. to its sites
of activity on DNA (Cappelli et a/., 1997). In addition, the model discussed above for the
possible role of Ap4A is also supported by other observations made previously in XRCC1-
deficient cells which would be consistent with the elevated level of ApysA/ADP-ribosylated
Ap,A and its proposed function. Characterisation of the XRCC1-deficient CHO strain EM9
has previously shownthat they show a delayed progression through S-phase, with a cell cycle
that is 33% longer thanin the parental strain AA8 (Kubota & Horiuchi, 2003). Furthermore,
they show a reduced rate of initiation of DNA replication, even in the absence of DNA
damaging agents (Thompson er al., 1990). Given the substantially elevated Ap4A levels
detected in EM9 cells and the apparent detection of ADP-ribosylated Ap4A, these
observations are consistent with a hypothesis that ApsA and/or its ADP-ribosylated
derivatives do have a role in slowing S-phase progression. This also presents a particularly
interesting possibility that some of the other characteristic phenotypes of EM9 and other
XRCC1-deficient cells may not be directly caused by the lack of XRCC1 per se, but rather
the accompanying increase in the level of intracellular ApsA. These phenotypesinclude a 10-
fold increase in the level of sister chromatid exchanges, defects in repairing SSBs and a
hypersensitivity to the monofunctional alkylating agents EMS and MMS (Thompson ef al.,
1982).
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Figure 6.1 Updated model for ApsA involvementin intra-S phase checkpoint control. (A)
Poly(ADPribose) polymerase 1 (PARP-1) binds to a SSB generated ahead of a replication
fork and forms a complex with DNA polymerase-f (pol-B), XRCC1 and DNAligase III
(Lig3a), as well as other DNA end-processing enzymes including aprataxin (APTX). Unable
to bind DNA immediately, Lig3a synthesises ApsA, which is then mono-ADP-ribosylated,
either by PARP-1 or by another protein such as PARP-2 whichis recruited during the later
stages of SSB repair. The mono-ADP-ribosylated Ap4A then binds to the Ap4A-bindingsite
on the pol-a-associated protein and inhibits it, possibly by reducingits interaction with DNA.
ADP-ribosylated Ap4A also diffuses throughout the nucleus and inhibits other replication
forks in the same way. (B) Auto-poly(ADP-ribosylation) of PARP-1 reduces its affinity for
DNAand allows pol-B and Lig3a to bind to the DNA and carry out the repair process.
Following repair, APTX may hydrolyse the excess Ap4A thus allowing DNAreplication to
continue. Diagram and model adapted and updated from McLennan, 2000.
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The mechanism by which ApsA and/or ADP-ribosylated ApsA may contribute to replication
fork stalling is not yet clear, although it still remainsa likely possibility that it acts through
the pol-a binding protein that has previously been shown to bind Ap4sA (Grummtef al., 1979;
Baril et al., 1983; Rapaport & Feldman, 1984; Baxi ef al., 1994). The identity of this protein
remains unknownbutit is notable that its two subunits appear to be of similar sizes to two of
the known isoforms of APTX (Moreira et al., 2001). While it seems an unlikely scenario,it is
interesting to speculate that APTX may actually be this pol-a associated Ap4A binding
protein. If this were the case, ApsA maybindto pol-a associated APTX, causing dissociation
of the polymerase from DNAandtherefore thestalling of DNA replication. Such situation
would be reminiscent of the role of Ap4A in binding to Hint-1 and disrupting its protein-
protein interaction with the transcription factor MITF (Lee ef al., 2004). Both Hint-1 and
APTXare related HIT superfamily proteins and share considerable sequence homology in
their HIT domains (Brenner, 2002). In this model, APTX could also subsequently hydrolyse
Ap4A (Kijas et al., 2004), causing a decrease in its levels and thus allowing subsequentre-
starting of DNA replication following damagerepair.
Aside from the potential mode ofaction through pol-a, there are alternative possibilities for
the mechanism by which Ap4yA may induce the delay of S-phase progression which could
also be considered. DNA replication begins only at defined sites ofinitiation, called origins
of replication. Theseare notall activated simultaneously and the primary means for slowing
down DNAreplication during S-phase is by inhibiting late firing origins of replication
(Tercero & Diffley, 2001). The two primary checkpoint-specific DNA damage sensing
proteins are ataxia telangiectasia mutated (ATM) and ATM and Rad3-related (ATR), both
members of the phosphatidyl inositol 3-kinase-like kinase (PIKK) family of protein kinases
(Savitsky et al., 1995; Cimprichet al., 1996). These proteins recognise various types of DNA
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damage which activates them to phosphorylate target proteins and induce multiple signalling
pathways. ATM and ATR phosphorylate the Chk2 and Chk1 proteins respectively (Zhou er
al., 2000; Guo et al., 2000), which in turn phosphorylate the transcription factor p53, thus
blocking its binding to MDM2 which normally targets it for degradation (Shieh ef al., 2000;
Hirao ef al., 2000). The increased levels of p53 activate transcription of p21 which then
inhibits Cdk2/cyclin E. Cdk2 has an important role in phosphorylating the pre-replication
complex (pre-RC), which facilitates loading of the replicative helicase cofactor Cdc45 onto
the origin of replication, thus activating it (Liu et al., 2006). Inhibition of Cdk2 therefore
prevents the initiation of replication. Activated Chk1 can also phosphorylate Cde25A which
leads to its ubiquitination and subsequent degradation. The result of this is that Cdc25A is no
longer able to carry out its usual function, which is to dephosphorylate Cdk2, thusactivating
the Cdk2/cyclin E or Cdk2/cyclin A complexes, which are required for the G1/S transition
and S-phase progression respectively (Zhao et al., 2002). Although these mechanisms
primarily act to slow DNAreplication by preventing initiation of late firing origins, it has
also been found that active replication fork progression can be slowed down in response to
DNAdamage(Seileref a/., 2007; Unsal-Kacmaz etal., 2007). The mechanism by whichthis
occurs is less well understood although it is notable that a requirement for Chk1 in
maintaining normalreplication fork progression has been reported (Petermann ef al., 2006).
Since Ap,A has beenreportedto inhibit various protein kinases (Levy et al., 1983) this raises
the interesting possibility that this function may be employed as part of a mechanismto slow
down S-phase progression in response to DNA damage. For example, since Chk] is required
for normal replication fork progression and fork slowing occurs in its absence (Petermann ef
al., 2006), this could be a potential target for Ap4A as a kinase inhibitor. Similarly, a number
of other proteins involved in the complex DNA damage checkpoint signalling cascade
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discussed above could also be potential targets for Ap4A to inhibit specific phosphorylation
events in order to slow S-phase progression, either by preventing the initiation of late firing
origins or by slowing fork progression. Such a role for ApsA would be a novel aspect of the
intra S-phase checkpoint to slow DNAreplication in response to DNA damage.
Although some of the checkpoint pathways for the inhibition of DNAreplication are already
fairly well characterised, this does not rule out a role for Ap4A. Given the importance of
maintaining the fidelity of DNA replication and control of cell division, it is not uncommon
for there to be multiple mechanisms of carrying out the same function in order to provide a
failsafe system. This is also seen in a number of other places such as the multiple
mechanismsfor preventing more than oneinitiation of each replication origin in a single cell
cycle (DePamphilis e¢ al., 2006).
Possibly the clearest indication of a functional involvement for Ap4A in the DNA damage
response is the finding that Ap4A-deficient cells generated by inducible overexpression of
NUDT2 ApsA hydrolase were more sensitive to EMS than wild-type cells. This provides the
first evidence of a direct importance for Ap4A in surviving DNA damage.It is unfortunate
that time constraints prevented further work on the cell line within the project, since it is
likely to be a valuable tool for examining the exact function of Ap4A and probing the
molecular details of this. One technique that is likely to be particularly informative is the
replication fork progression assay (used in Henry-Mowatt ef al., 2003; Petermann ef al.,
2006). This involves pulse labelling active replication forks for 20 minutes with
bromodeoxyuridine (BrdU), which is incorporated into the length of DNA strands
synthesised during that time. Following this treatment, the cells are washed to remove
unincorporated BrdU andthe replication forksare pulse labelled with iododeoxyuridine (IdU)
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for a further 20 minutes while simultaneously subjected to a DNA damagingagent. Thecells
are then fixed on slide and both BrdU and IdU are detected by different labelled antibodies.
For a number of different replication forks, the length of BrdU-incorporated DNA is
measured and usedto calculate the fork progression rate during the initial 20 minutes before
DNA damage wasinduced. The length of DNA with IdU incorporated is also measured for
each fork and usedto calculate the fork progression rate for the 20 minutes following DNA
damage induction. These two values are then compared to assess what effect the DNA
damage has on fork progression rate. If the ApsA-deficient cell line shows a reducedability
to slow downreplication fork progression in response to DNA SSBs, this would indicate an
involvement for Ap4A in the process.
The possible role of ApsA proposed here to slow S-phase progression in response the
detection of DNA damageis not incompatible with other suggested roles, such as an inducer
of apoptosis under certain conditions. It is certainly conceivable that increased intracellular
Ap,A may have quite different effects depending on the magnitude of the increase. Where
there are relatively low levels of DNA damage, a moderate increase in the level of ApsA
occurs, such as the 2.1-fold increase reported here following EMStreatment, which mayact
to stall DNA replication to allow time for repair. However, it is clear that much larger
increases in Ap4A can also occur such as the 13-fold increase following treatment with EMS
and araC which presumably results in a very high level of strand breaks. Such a large or
persistent accumulation of Ap4A in the cell could have the different effect of inducing
apoptosis (Vartanian ef al., 1999). Therefore ApyA may act as an important signalling
molecule integrating both DNA checkpoint control and apoptosis. Such a role would in some
ways be analogous to that of the well-known tumour suppressor gene p53, which has a
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function in signalling pathways to inducecell cycle arrest or to initiate apoptosis dependent
on various factors.
The proposed role of Ap4sA as a signalling molecule in the DNA damageresponseis also not
incompatible with its reported role as an activator of transcription under certain other
conditions.It has already been suggested that the accumulation of Ap4A produced in response
to different stimuli could arise from difference sources based on the differing dynamics of
accumulation over time (Gilson ef al., 1988) and the fact that ApyA is known to be
synthesised by a wide range of different enzymes. The Ap4sA produced during mastcell
activation appears to be produced by LysRS (Yannay-Cohenef al., 2009) and is believed to
activate MITF-dependenttranscription of various genes by binding to the repressor protein
Hint-1 (Lee et al., 2004). However, the activation of transcription appears to require a very
high concentration of ApsA and importantly, LysRS directly binds to its target protein
complex to synthesise this ApyA (Lee etal., 2004). This is likely to produce very highlevels
of Ap4A in the vicinity of these molecules, which may be required for its effect on Hint-1.
There is no indication that LysRS is activated in response to DNA damageand it seemsfar
more plausible that Lig3a is responsible for ApsA accumulation in this case. As part of a
different protein complex, this could have an entirely different effect. Indeed, the XRCC1-
Lig3a complex directly interacts with PARP-1, which may be important for the ADP-
ribosylation of Ap4A andtherefore its proposed function in replication forkstalling.
Aninteresting additional possibility for the function of Ap4A could be to act as an ‘adenylate
sink’ to allow the re-generation of free Lig3a from Lig3a-AMP. The majority of cellular
Lig3a is thought to exist as Lig3-AMP and this is the form that is required for ligation of
conventionalsingle strand nicks. However, non-adenylated Lig3 may specifically be required
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to join prematurely 5' adenylated ends that have been found to occur during the attempted
ligation of non-conventional DNA ends (Reynolds ef al., 2009). If this were the case, ATP
would be a better AMP acceptor from Lig3a-AMP than PP; because of its much higher
intracellular concentration, thus resulting in the production of Ap4sA. This proposed function
for free Lig3a would complement that of APTX, which is already known to de-adenylate
AMP-linked 5' ends to produce a conventional terminus whichis a substrate for Lig3a-AMP
(Ahelef al., 2006). In XRCC1-deficientcells, the increased level of ApsA could be dueto the
uncoupling of Lig3 from its multiprotein repair complex and DNA which maylead to rapid
turnover of Lig3-AMP. This additional potential function for ApsA does not preclude the
other functions discussed above.
In summary,this study has madea significant contribution to our understandingofthe role of
intracellular ApsA and has gathered considerable evidence supporting its involvementin the
DNAdamageresponse. Although significant progress has been madein elucidating the exact
role of Ap4A, therearestill aspects of this that remain unclear. This project has opened up an
interesting new area of study and has provided newinsights into the possible role for Ap4A in
cell signalling that has so far remained unknown.It is clear that there are manyinteresting
possibilities for future investigation in this area and that the findings will add to our already
detailed molecular understanding of an essential biological process, the DNA damage
response.
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